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Abstract 
Many health care systems in low income settings define essential health packages (EHP) to 
concentrate scarce resources on key health interventions to which their populations can have free 
access at the point of delivery.  Malawi has used EHPs since 2004 but they have generally included 
unaffordable interventions that have not been fully delivered.   
 
To guide decisions about the 2016 EHP in Malawi, an analytical framework is proposed that 
identifies interventions which, based on currently available evidence, offer the most gains in 
population health.  The framework uses existing estimates of what the Malawian health care system 
is currently able to afford to generate gains in health  W a measure of health opportunity costs.  This 
facilitates an initial quantification of an appropriate budget for the EHP, and of the interventions that 
might be included which can then be prioritised on the basis of their expected impact on population 
health assuming 100% implementation.   
 
In practice, lower levels of implementation will be achieved by interventions due to various 
constraints operating on the demand or supply side, and which apply to specific interventions or the 
system more generally.  The framework provides an analytical basis to consider the implications for 
population health of these different types of constraints.  It uses this as a basis of assessing how the 
underspend on the EHP due to ƚŚĞ ?ŝŵƉůĞŵĞŶƚĂƚŝŽŶŐĂƉ ?ĐĂŶďĞƵƐĞĚ ?dŚĞĨƌĂŵĞǁŽƌŬĞƐƚŝŵĂƚĞƐƚŚĞ
potential impacts on health outcomes of intervention-specific implementation activities and system 
strengthening.  These potential impacts are compared with the health outcomes offered by 
extending the package to include additional interventions. 
 
The analytical framework can also assess the implications for population health of the types of 
constraints that donors may impose on their funding schemes in health care.  These constraints can 
include requiring that particular interventions are included in the EHP when the funding could have a 
bigger impact on health if spent elsewhere; offers to expand the package but restricted to particular 
interventions and forgoing greater health outcomes elsewhere; and offers to provide additional 
funding as long as these are matched by government. In negotiating with donors and communicating 
with relevant stakeholders, policy makers will benefit from understanding the implications for 
population health of such constraints.  
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Executive summary 
1. Policy context and purpose 
Malawi has had an Essential Health Package (EHP) since 2004.  The criteria employed to determine 
which interventions within programmes to include have resulted in an unaffordable package that is 
only available and free at the point of care on paper. In reality there are significant gaps in the 
coverage of essential interventions, with parts of the country, particularly rural areas, able to offer 
only very limited and uncertain access for those in most need.  This also places those seeking 
essential care, which in reality may be unavailable within the public system, at significant financial 
risk.  
 
The 2011-16 package used a prioritisation strategy based on disease burden and cost-effectiveness, 
but without proper consideration of what the Malawian health system was able to achieve with 
existing levels of available expenditure (health opportunity costs).  The resulting recommended 
package  W if fully implemented  W would have required substantially more public resources than 
ǁĞƌĞ ?ŽƌĐŽƵůĚŚĂǀĞďĞĞŶ ?ŵĂĚĞĂǀĂŝůĂďůĞƚŽDĂůĂǁŝ ?ƐDŝŶŝƐƚƌǇŽĨ,ĞĂůƚŚ ?/ŶĂĚĚŝƚŝŽŶ ?ƚŚĞŵŝǆŽĨ
selected interventions and programmes did not properly prioritise within the package or reflect on 
likely levels of implementation due to supply and demand constraints.  It also included some 
interventions where the resources required (even if they had been available) could have had a 
greater impact on health if they had been devoted to interventions and programmes that were 
excluded or not fully implemented.   
 
To support decisions regarding the 2016-21 package requires an analytical framework that can 
support a decision making process focused on improving health outcomes overall.  This requires 
available evidence on the costs and health effects of candidate interventions to be identified, 
together with empirical evidence on health opportunity costs that reflects what Malawi is currently 
able to afford to pay to improve health (cost per DALY).  Together, this evidence can be used to rank 
candidate interventions within programmes for the EHP in terms of their overall likely impact on 
population health.  
 
Inevitably, there are constraints on the levels of implementation that are feasible for EHP 
programmes.  Some of these constraints operate at the level of the specific intervention or 
programme:  constraints on the supply side (e.g. limited skilled staff) and demand side (e.g. travel 
distance for patients and/or adherence to treatments).  Other constraints relate to the health 
system, again on the supply side (e.g. unreliable availability of power and water) and demand side 
(the ability to raise public finance to support spending Ministries including Heath).  Comparing the 
impact of programmes on population health with and without these constraints provides an 
indication of the maximum gains of efforts to relax constraints and strengthen the health care 
system.  This can inform decisions about using some of the resources available for the EHP (or 
making more resource available from outside the EHP) for system strengthening, such as investment 
in infrastructure and assuring effective supply of products and training of skilled labour.  
 
Analysis is needed which also helps decision-makers understand and communicate the implications 
of donor-imposed constraints and guide their policy responses.  This framework provides an 
estimate of the gains in population health that would be possible if the Ministry of Health had an 
unconstrained choice of which interventions it includes in the EHP.  It provides a baseline against 
which to compare the effects of donor-imposed conditions on population health, rather than 
allowing the additional donor funds to be used for whatever intervention or implementation activity 
the available evidence suggests will generate the greatest impact on health outcomes.   
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Decision-makers may also wish to consider a range of objectives in addition to gains in population 
health, e.g. interventions which promote financial protection more than others or to reduce health 
inequalities.  If evidence is available, the analytical framework could be extended to include these 
other considerations.  A primary focus on health can, however, inform decisions about the inevitable 
trade-offs with other objectives, and more political considerations, based on changes in population 
health. 
 
2.  Informing health care decisions: the importance of health opportunity costs 
To decide whether an intervention will improve health outcomes overall and should be regarded as 
cost-effective, a comparison is required with an assessment of the likely health opportunity costs.  
dŚŝƐŝƐĐŽŵŵŽŶůǇĚĞƐĐƌŝďĞĚĂƐĂĐŽŵƉĂƌŝƐŽŶǁŝƚŚĂ ?ĐŽƐƚ-efĨĞĐƚŝǀĞŶĞƐƐƚŚƌĞƐŚŽůĚ ? ?DƵĐŚŽĨƚŚĞ
published literature of such thresholds, and the values recommended, reflect a lack of conceptual 
clarity.  None represents what is required:  an evidence based assessment of the likely health 
opportunity costs.   
 
Recent research has demonstrated that an empirical assessment of health opportunity costs is 
possible based on estimates of the health effects of changes in health care expenditure.  Empirical 
work has been extended to low- and middle-income countries (LMICs) reflecting factors such as their 
demography, epidemiology, health care expenditure and income.   
 
Such cost-ĞĨĨĞĐƚŝǀĞŶĞƐƐ ?ƚŚƌĞƐŚŽůĚƐ ?ĂƌĞŶŽƚĚĞĐŝƐŝŽŶ ?ƌƵůĞƐ ?ďƵƚƉƌŽǀŝĚĞĂďĞŶĐŚŵĂƌŬƚŽƐĞĂƌĐŚĨŽƌ
and identify other under exploited investments that could offer greater value, and existing 
commitments that could be disinvested to accommodate more valuable ones.  Such estimates 
ensure that decisions based on cost-effectiveness analysis improve rather than reduce health 
outcomes overall.  
 
An assessment of the likely health opportunity costs makes it clear that health care costs matter 
because they represent the opportunity to improve the health of others who could benefit from 
health care.  An empirical assessment of health opportunity costs makes the strong ethical 
foundation of cost-effectiveness analysis less abstract and more easily communicated to the range 
of stakeholders.  This can help make the politically difficult decisions of what programmes and 
interventions can be included in the EHP (and which cannot) a more accountable, evidence based 
and, therefore, sustainable prospect. 
 
Existing evidence of the effect of changes in health expenditure on health outcomes has been 
marshalled in recent studies to inform an assessment of health opportunity costs in LMICs.   This 
research suggests that the cost per DALY is typically lower (health opportunity costs are typically 
higher) in lower income settings.  The GDP per capita-based thresholds that have become widely 
used to judge cost effectiveness in LMICs are likely to be significantly higher than an assessment of 
health opportunity costs.  
 
Estimates of health opportunity costs are presented that indicate what the current evidence 
suggests Malawi is currently paying to avert a DALY. Once the health that is likely to be delivered by 
greater health care expenditure is set out, it then becomes possible to have a more meaningful 
ĚĞůŝďĞƌĂƚŝŽŶĂďŽƵƚŚŽǁDĂůĂǁŝ ?ƐƉƵďůŝĐĨŝŶĂŶĐĞƌĞƐŽƵƌĐĞƐŵŝŐŚƚďĞĂůůŽĐĂƚĞĚďĞƚǁĞĞŶĐŽŵƉĞƚŝŶŐ
claims and how increases in public finance might be achieved. 
 
3.  Supporting the development of an EHP in Malawi 
An analytical framework is developed and illustrated, and its implications for the Malawian EHP 
considered.  In developing this framework, the best data currently available has been brought 
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together, but this can be improved upon and extended over time.  The main purpose is to show the 
principles of the analytical framework, how it can guide a range of important policy questions and its 
implications for the EHP based on currently available evidence.  A series of analytical steps is taken: 
 
The appropriate scale of the EHP.  This is initially based on the empirical estimates of health 
opportunity costs in Malawi (cost per DALY).  This provides a means of identifying candidate 
programmes for the EHP that are expected to generate health at a cost that is consistent with what 
Malawi can currently afford.  The cost of these candidate programmes provides information on the 
size of the budget that might reasonably be devoted to the EHP.  On the basis of an estimated health 
opportunity cost of $61 per DALY averted, 48 of the candidate programmes can be afforded.  
Together, and assuming full implementation, these would cost $264.5 million per annum that can be 
considered an appropriate budget for the EHP.  The framework allows the total costs and health 
effects, if Malawi could afford to pay more (or less) to improve health (a higher or lower cost per 
DALY), to be considered. 
 
Maximising gains in population health from the available budget.  Ranking of interventions is not 
possible based on their cost per DALY estimates.  Rather it needs to consider the health gains for the 
population that can benefit from an intervention net of the health opportunity costs of the total 
resources required to deliver it (net DALYs averted).  
 
Informing decisions regarding implementation and system strengthening.  The impact on population 
health of the programme-specific and system-ůĞǀĞůĐŽŶƐƚƌĂŝŶƚƐƚŚĂƚƌĞƐƵůƚŝŶĂŶ ?ŝŵƉůĞŵĞŶƚĂƚŝŽŶŐĂƉ ?
is reported.  The magnitude of the budget underspend associated with less than full implementation 
is also presented.  
 
Prioritising programme-specific implementation activities.  A range of policy options exist to address 
the constraints facing specific programmes that result in less than full implementation, and can 
relate to the demand side or supply side. Prioritisation of such activities by programme is informed 
by the magnitude of loss in population health net of health opportunity cost (net DALYs averted).   
 
Informing policy on system-level constraints and system strengthening.  The framework provides an 
indication of the maximum potential value of system strengthening and can support decisions 
regarding whether such policies should be prioritised over programme-specific activities.  This can be 
considered alongside the underspend on the budget due to partial implementation but reflecting the 
fact that, although longer-term health benefits may be realised from a stronger health system, there 
would be no immediate health gain if all the EHP underspend was devoted to system strengthening.  
 
Accepting current levels of implementation and funding additional programmes. Rather than using 
the underspend on the EHP budget due to partial implementation on implementation activities and 
system strengthening, it could, instead, be devoted to extending the package by including additional 
programmes that were initially excluded.  The framework presents the additional programmes that 
could be included at realistic implementation levels, and the impact on population health, i.e., 
simply accepting existing constraints and system weaknesses. 
 
Assessing the implications of donor-imposed constraints.  The framework also considers the 
implications for population health of another type of constraint  W those imposed by donors. Four 
types of donor constraint and their potential health opportunity costs are considered:  a 
requirement that a particular programme is included in the EHP (when a bigger impact on health 
outcomes is possible if the resources where spent elsewhere); an offer to expand the package but 
restricted to a particular programme (when greater health outcomes could be generated by 
spending elsewhere); an offer to provide additional funding as long as this is matched by the 
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Malawian Ministry of Health and conditional on the funding going on a particular programme; and 
an offer to provide additional funding as long as this is matched with additional health care 
expenditure, but without a condition that the funding goes on a particular programme.  
 
4. Establishing and implementing an Essential Health Package 
Given that a number of the key considerations in developing the EHP are subject to rapid change 
over time, there is a strong case for the Malawian Ministry of Health to provide more frequent 
assessment of the scale of the package, the interventions to be included and the funding of 
intervention-specific implementation activities and system strengthening.  
 
The framework uses currently available evidence on the health opportunity cost and the costs and 
effects of the range of candidate interventions for the EHP.  International work on health 
opportunity costs relevant to individual jurisdictions is central to evidence-based resource allocation 
decisions, and providing a more precise estimate for Malawi is likely to be a priority research area.   
The evidence on the costs and effects of potential EHP interventions used in the framework to date 
needs further development.  
 
It is important to emphasise that the analytical framework and the results it has generated so far is 
not to specify a list of interventions that ought to be included in the EHP.  Rather, this analysis is 
intended to support the decision making process of the Ministry of Health.  It can be used to engage 
with a range of relevant stakeholders and more effectively communicate the difficult choices, 
inevitable trade-offs and considerations to wider communities.  
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1. Policy context and purpose 
 
1.1 Essential Health Packages in Malawi 
Malawi has had an Essential Health Package (EHP) since 2004 (Appendix 1 provides a brief summary 
of the plans and how they were developed).  The initial version (2004-9) focussed on reducing infant 
and under-five mortality, improving maternal mortality rates, preventing HIV and reducing 
population growth.  The revised package, developed in 2011, sought to use disease burden and 
 ?ĐŽƐƚ-ĞĨĨĞĐƚŝǀĞŶĞƐƐ ?ĂƐĂďĂƐŝƐŽĨĞǆƉĂŶĚŝŶŐƚŚĞ,WŝŶƚĞƌǀĞŶƚŝŽŶƐĨŽƌŶŽŶ-communicable diseases 
and some surgical procedures.  The criteria employed for this expansion, however, resulted in an 
unaffordable package as it was estimated to cost 83-132% of total health expenditure across the five 
years of the package (Appendix 1).  This has resulted in a package that is only theoretically available 
and publicly funded for those who need it.  In reality local availability has been limited, as stocks of 
relevant products have been exhausted as financial resources run out.   
 
The challenge of achieving an affordable and sustainable EHP in the 2011-16 period requires a 
careful consideration of the lessons to learn from the criteria that were employed in defining that 
package.  A prioritisation strategy was developed that, firstly, identified potential interventions 
relating to diseases with high burden; a second strand to the strategy considered what was termed 
 ?ĐŽƐƚ-ĞĨĨĞĐƚŝǀĞŶĞƐƐ ? ?EĞŝƚŚĞƌĞůĞŵĞŶƚŽĨƚŚŝƐƐƚƌĂƚĞŐǇ ?ŚŽǁĞǀĞƌ ?ĚŝƌĞĐƚůǇĐŽŶƐŝĚĞƌĞĚƚŚĞŽǀĞƌĂůů
impact of interventions on overall population health factoring in the health outcomes the Malawian 
health system was already able to achieve from its expenditure (health opportunity costs).   
 
Initial prioritisation using disease burden identified disease areas affecting large populations, 
interventions for which had potentially high budget impacts but would not necessarily impact 
significantly on burden.  The cost-effectiveness aspect of prioritisation failed to consider the rate at 
which the Malawian health sector was already generating gains in population health.  This resulted 
in a recommended package that  W if fully implemented  W would have absorbed too great a 
ƉƌŽƉŽƌƚŝŽŶŽĨDĂůĂǁŝ ?ƐŽǀĞƌĂůůŚĞĂůƚŚĐĂƌĞƌĞƐŽƵƌĐĞƐĂŶĚĚŝǀĞƌƚĞĚƚŽŽŵƵĐŚĨƵŶĚŝŶŐĂǁĂǇĨƌŽŵ
interventions that could generate greater health outcomes than those recommended (i.e. the health 
opportunity costs would have been considerable). 
 
1.2 Prioritising the 2016 Essential Health Package: development of a framework 
It is important to learn from the limitations of the 2011 methods and to develop an appropriate 
framework for guiding decisions about the EHP in 2016.  This framework would put the objective of 
increasing overall population health at the centre of defining an EHP.  This requires the use of best 
evidence on the costs and health effects of interventions.  It also needs to use available empirical 
evidence on health opportunity costs that reflects the rate at which the Malawian health system is 
currently able to generate health improvement from its expenditure.  This evidence-based 
assessment will mean that estimates of cost-effectiveness can better inform prioritisation decisions, 
and that these decisions improve - rather than reduce - health outcomes overall (Drummond et al., 
2015). 
 
1.2.1 Determining what interventions enter the EHP 
An appropriate analytical framework to guide decisions needs to establish a set of candidate 
interventions.  This should be informed by the available empirical evidence on what Malawi is 
currently able to afford to improve health.  That is, the rate at which Malawi is currently able to 
translate its public expenditure on health care into heath improvements for its population.  To 
consider including interventions in the EHP that require more expenditure to improve health than 
the overall system currently needs would not make sense: it would make less effective use of 
resources and reduce population health.  Similarly, to limit the EHP only to interventions that require 
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lower expenditure to generate health outcomes than the overall system would be inappropriate 
because Malawi could afford to allocate more funding to the EHP and improve overall population 
health.  
 
The framework would then be able to prioritise these candidate interventions for the package.  This 
is achieved by establishing a ranking, based on available evidence, in terms of impact on population 
health.  This needs an assessment of the magnitude of health gain for the average patient over and 
above how much health improvement could have been generated with the same level of public 
expenditure elsĞǁŚĞƌĞŝŶƚŚĞƐǇƐƚĞŵ ?ŝ ?Ğ ?ƚŚĞĂǀĞƌĂŐĞƉĂƚŝĞŶƚ ?ƐŚĞĂůƚŚŽƵƚĐ ŵĞƐŶĞƚŽĨŚĞĂůƚŚ
opportunity cost).  This net health effect per patient is then scaled by the size of the recipient 
population; the larger the overall number of patients who stand to benefit from an intervention, the 
greater the overall impact on population health.   
 
The framework would make clear the implications for population health of devoting more or less 
overall funding to the EHP.  There is inevitable uncertainty associated with empirical estimates of 
what Malawi can currently afford to pay for health care.  However, by running different scenarios 
regarding this estimate, it is possible to show the implications for the interventions that could be 
included in the package, the implied EHP budget, and the gains in population health associated with 
expected levels of implementation of those interventions. 
 
1.2.2 Implementation levels and enhancement 
Ideally a given intervention would reach the entire patient population that stands to benefit from it.  
In reality, however, there are constraints on the levels of implementation that are feasible for EHP 
interventions (Mills (1994) and Hanson et al. (2003)).  Some of these constraints operate at the level 
of the specific intervention ?KŶƚŚĞ ?ƐƵƉƉůǇƐŝĚĞ ? ?ƚŚĞŚĞĂůƚŚƐǇƐƚĞŵŵĂǇ ?ĨŽƌĞǆĂŵƉůĞ ?ŚĂǀĞĂůŝŵŝƚĞĚ
ŶƵŵďĞƌŽĨƐƉĞĐŝĨŝĐƐŬŝůůĞĚƐƚĂĨĨŽƌĂƐŚŽƌƚĂŐĞŽĨĂƉƉƌŽƉƌŝĂƚĞĞƋƵŝƉŵĞŶƚ ?KŶƚŚĞ ?ĚĞŵĂŶĚƐŝĚĞ ? ?
patients may fail to initiate or to continue a treatment from which they are expected to benefit, 
perhaps due to an associated social stigma.  Other constraints relate to the health system more 
generally and impact on the implementation of all interventions ?^ƵĐŚ ?ƐǇƐƚĞŵǁĞĂŬŶĞƐƐĞƐ ?ŵŝŐŚƚ
include, on the supply side, unreliable availability of power and water, inefficiencies or bottlenecks 
in the procurement of products, and a lack of hospital beds or clinic space.  On the demand side, 
system-level constraints might relate to the travel distance patients have to make to access care.  
 
An analytical framework seeking to support decisions about an EHP needs to incorporate realistic 
rates of implementation for each candidate intervention.  This provides an estimate of health 
outcomes that are feasible based on expected levels of implementation.  This estimate can be 
compared with the health outcome that is expected to be achieved in the absence of supply or 
demand side constraints  W ƚŚĂƚŝƐ ?ƚŚĞŚĞĂůƚŚŐĂŝŶƐĨƌŽŵƌĞŵŽǀŝŶŐƚŚĞ ?ŝŵƉůĞŵĞŶƚĂƚŝŽŶŐĂƉ ?ĂŶĚĂůů
patients ultimately receiving the interventions for which they are eligible (Fenwick, Claxton and 
Sculpher, 2008).  This comparison is important to guide decisions because it provides an indication of 
the maximum gains in population health that would be achieved if policies were available to remove 
all supply and demand side constraints to take implementation to 100%.  This shows to decision 
makers the maximum potential value of investing resources system strengthening policies - such as 
investment in infrastructure, assuring effective supply of products, and training of skilled labour  W 
that can increase implementation across interventions in the EHP.   
 
Furthermore, the maximum potential gains in population health from policies to remove gaps in 
implementation will vary across interventions.  The magnitude of these gains will depend on the per-
patient net health effects (allowing for health opportunity costs) and the absolute number of 
patients who are not receiving the intervention that is appropriate for them.  These estimated 
maximum potential gains for individual interventions inform decisions regarding whether to invest in 
intervention-specific initiatives to increase implementation and how to prioritise across 
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interventions.  On the demand side these implementation activities may include conditional cash 
transfers to patients to incentivise update and adherence.  On the supply side possible policies may 
involve staff training or the purchase of equipment.  If less than full implementation of one or more 
interventions is related to a failure by districts or providers to organise services appropriately, 
consideration could be given to how to incentivise those organisations to deliver EHP interventions. 
 
These examples indicate that many of the policies to address supply and demand side constraints  W 
at a system or intervention level  W involve investments that draw on financial resources from the 
EHP budget.  This may not be the case for all implementation-enhancing activities  W for example, 
donors or central government might be willing to fund system strengthening from outside the 
package.  The implementation gap not only results in lower levels of population health than could be 
achieved with 100% implementation of interventions, it also means the EHP budget is underspent. 
Some proportion of this underspend can be allocated to increase implementation.  Making clear the 
maximum potential gain in population health associated with removing the implementation gap (at 
intervention and system level) provides an initial indication of the scale of benefit from 
implementation-enhancing activities and system strengthening.  Ultimately, however, best available 
evidence on the costs and effectiveness of specific activities will need to be assessed to determine 
whether any such investment is funded and, if so, which particular types of implementation initiative 
or health system strengthening receives this funding.   
 
Such assessments might conclude that implementation and system strengthening activities are not 
feasible or that their costs cannot be justified on their expected impact on population health.  It may 
then be appropriate to retain existing interventions at less than 100% implementation and to use 
the budget underspend in adding interventions to the EHP.  Expected gains in population health by 
extending the package in this way can be contrasted with what would be possible if full 
implementation of a more restricted package had been feasible.   
 
1.2.3 Examining donor-imposed constraints 
An analytical framework to guide EHP decisions should also provide a basis to understand the 
implication of donor-imposed constraints and to guide policy responses.  Following the principles 
outlined above, this can be achieved by using best evidence to estimate the gains in population 
health associated with the Malawian Ministry of Health having an unconstrained choice of which 
interventions ŝƚŝŶĐůƵĚĞƐŝŶƚŚĞ,W ?dŚŝƐƉƌŽǀŝĚĞƐĂ ?ďĂƐĞůŝŶĞ ?ĂŐĂŝŶƐƚǁŚŝĐŚƚŽĐŽŵƉĂƌĞƚŚĞĞĨĨĞĐƚƐ
of donor-imposed conditions on population health.  For example, a donor may be willing to provide 
additional funding for the EHP but only on a specific intervention which, available evidence suggests, 
is not sufficiently effective given its additional cost to be included in the EHP with the existing budget 
or an increased one through the donor contribution.  The framework can then quantify the cost to 
population health of the donor imposing a particular intervention on the EHP rather than allowing 
the health system to use additional donor funds to invest in whatever activity or intervention the 
available evidence suggests will generate the greatest impact on overall health.   
 
^ƵĐŚĂŶĂŶĂůǇƐŝƐĐŽŵƉĂƌŝŶŐƚŚĞŚĞĂůƚŚďĞŶĞĨŝƚƐŽĨƚŚĞĚŽŶŽƌ ?ƐƉƌŽƉŽƐĂůǁŝƚŚƚŚĞŚĞĂůƚŚŽƉƉŽƌƚƵŶŝƚǇ
cost can inform a discussion with donors about the need to impose constraints on their funding, and 
to engage stakeholders in understanding the implications of particular policy options regarding 
donor offers.  Such options would include accepting the donor proposal but being clear about the 
health opportunity costs of doing so; rejecting donor funding with constraints thus avoiding the 
damage of the imposed intervention but losing the benefit that could be achieved with donor 
funding; and accepting the proposal but using policies to mitigate the worse effects of the donor-
imposed constraints (e.g. use of user fees to deter uptake of the imposed intervention). 
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1.2.4 Arrangements between the national EHP and districts 
The analytical framework can be conceptualised to guide national decisions about which 
interventions to include in the EHP and the commensurate level of budget, and to guide decisions 
about implementation activities, system strengthening, and donor proposals.  The framework can 
also provide a guide to the choice of policies regarding the role of districts in delivering the EHP.  
Districts will vary according to the needs of their populations for interventions within the EHP, and 
the framework provides a means of quantifying the financial resources that will need to flow from 
the centre to each district to fund EHP interventions given levels of need.   
 
The constraints discussed above that prevent full implementation of the interventions are also likely 
to vary between districts.  Furthermore, the balance between intervention-specific factors and 
system weaknesses that explain the implementation gap are unlikely to be the same for each 
locality.  The analytical framework can guide Ministry of Health policies regarding implementation at 
the district level.  In particular, there will be a balance to strike between the objectives of the 
funding that flows from the centre to the districts.  That funding should reflect district-specific levels 
ŽĨŶĞĞĚ ?ďƵƚŵĂǇĂůƐŽƚĂŬĞĂƐŐŝǀĞŶƚŚĞůŽĐĂůƐǇƐƚĞŵ ?ƐĞǆƉĞĐƚĞĚůĞǀĞůƐŽĨŝŵplementation that may 
be markedly less than 100%, reflecting intervention-specific and system-level constraints.   
 
As at the national level discussed above, there is also scope to use the underspend from less than 
100% intervention implementation at local level to address intervention-level constraints or to 
invest in system strengthening.  Such investments may seek to incentivise more extensive 
implementation of the EHP; for example, by making funding for system strengthening conditional on 
evidence of improved implementation of EHP interventions.  By making the net impact on 
population health explicit, the analytical framework can help to shape an evolving resource 
allocation mechanism between the Ministry of Health and districts. 
 
1.2.5 Considerations other than health 
Inevitably, the Ministry of Health and stakeholders may want to consider a range of objectives in 
addition to gains in population health when making decisions about what interventions to include in 
the EHP.  These might include, for example, using interventions to promote financial protection or to 
reduce health inequalities, and recognising the impact of interventions on wider social objectives 
such as productivity.  In principle, it is possible to extend the measure of benefit and opportunity 
cost to include these other considerations (Asaria, Griffin and Cookson (2015) and Verguet, 
Laxminarayan and Jamison (2015)).  In practice, this may be challenging based on available evidence, 
in which case it is possible to inform decisions about relevant trade-offs based on changes in 
population health (Drummond et al., 2015).    
 
As discussed, a framework based on the objective of changes in population health will consider the 
health benefits of a specific intervention and the health opportunity costs associated with its cost at 
realistic levels of implementation.  If a decision maker is considering the inclusion of an intervention 
in the EHP that cannot be justified in terms of gains in population health (e.g. due to anticipated 
gains in wider social benefits), the implications of such a decision for net health outcomes should be 
clear.  In other words, the decision making associated with the selection of interventions for the EHP 
will inevitably need to consider a range of factors; the analytical framework can provide a clear 
quantification of the health opportunity costs associated with such a decision.  The transparency 
associated with this trade-off should support the accountability of funding decisions. 
  
Supporting the development of an essential health package: principles and initial assessment for Malawi  5 
 
1.3 Guide to this report  
The next section of this report develops the keys concepts around health opportunity costs, 
describes the emerging empirical evidence relating to these metrics and shows how important they 
are in guiding resource allocation decisions.   
 
Section 3 describes the analytical framework that has been developed to inform decisions about the 
selection of interventions for the EHP in Malawi.  It uses available data to draw out insights into 
which interventions are consistent with increasing population health.  Finally, Section 4 offers some 
conclusions and comments on how the framework can contribute to decision making in Malawi. 
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2. Informing health care decisions: the importance of health opportunity costs 
 
2.1 Introduction 
Decision makers in all countries (whether low, medium or high income), face difficult decisions 
about how to use the resources available for health care to achieve the greatest improvement in 
agreed social objectives.  They also need to decide how much of the available resources should be 
devoted to health care. 
 
An important objective of health care expenditure is to improve health itself, which includes 
improvements in survival and reductions in morbidity.  This requires an assessment of whether the 
improvement in health outcomes offered by investing additional resources in an intervention (which 
may be a technology, a service or a whole pathway of care) exceeds the improvement in health that 
would have been possible if the resources required had, instead, been made available for other 
health care activities.  Therefore, some assessment of these health opportunity costs is required if 
the best use is to be made of available resources.  
 
Methods of analysis to estimate the expected costs and health effects of the range of alternative 
interventions available to improve the health of a specific population with a particular indication are 
well developed (Drummond et al., 2015).  The results are commonly summarised as incremental 
cost-effectiveness ratios (ICERs), which provide a useful summary of how much additional resource 
is required to achieve a measured improvement in health (e.g. the additional cost per Disability 
Adjusted Life Year (DALY) averted), or how much health is delivered for an amount of resource (e.g. 
the DALYs averted per $1,000). 
 
However, to decide whether the intervention will improve health outcomes overall (and should be 
regarded as cost-effective) a comparison is required with an assessment of the likely health 
opportunity costs.  This is commonly described as a comparison with a cost-effectiveness threshold 
(Drummond et al., 2015).  To date much effort has been devoted to assessing the incremental costs 
and effects of interventions but there remains much confusion about what a cost-effectiveness 
threshold ought to represent and what type of evidence might inform its assessment.  As a 
consequence much of the published literature and the values recommend or cited by decision 
making and advisory bodies (both national and supra national) reflects a lack of conceptual clarity 
(see Section 2.4). None represent what is required; an evidence based assessment of the likely 
health opportunity costs (Revill et al. (2014) and Culyer (2015)).   
 
Recent research has demonstrated that an empirical assessment of health opportunity costs is 
possible based on estimates of the health effects of changes in health care expenditure (Claxton et 
al., 2015a).  This has been extended to estimating health opportunity costs for LMICs (Woods et al., 
2015), reflecting their demography, epidemiology, health care expenditure, income and other 
characteristics (Ochalek, Lomas and Claxton (2015)).  It is now possible to make real what was 
previously an abstract concept (see Section 2.3).  An assessment of health opportunity costs in 
Malawi can support decisions about which programmes and interventions might be included in an 
EHP, what the scale of the EHP might be and how efforts to implement interventions might be 
prioritised.  It also allows the health opportunity costs of the other constraints that decision makers 
face (including restrictions placed on assistance by donors) to be identified.  These assessments can 
be used to prioritise aspects of health care system strengthening and negotiate more effectively 
with donors on how their assistance can best meet DĂůĂǁŝ ?ƐŚĞĂůƚŚĐĂƌĞŶĞĞĚƐ ? 
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2.2 The role of health opportunity costs 
An explicit and evidence based assessment of health opportunity costs means that estimates of cost-
effectiveness can better inform prioritisation decisions.  Most importantly it ensures that decisions 
based on cost-effectiveness analysis improve rather than reduce health outcomes overall.  It also 
makes it possible to directly compare the health benefits and health opportunity costs of an 
intervention.  The expected net health benefits (net DALYs averted) represent the potential net 
health impact of ensuring an intervention is fully implemented.  The value of the intervention can 
also be expressed in monetary terms as the amount of additional health care resources that would 
be equivalent to the net health benefits it offers (the $ value to the health care system). 
 
2.2.1 The importance of health opportunity costs 
The importance of an assessment of health opportunity costs is illustrated in Figure 1, based on a 
stylised example of a new intervention (T1) compared to existing provision (T0 = no active 
treatment) for a specific population1.  The new intervention offers additional health benefits of 
200,000 DALYs averted, if fully implemented, at an additional cost of C1=$20mn.  Therefore, the 
intervention offers one DALY averted for every additional $100 spent.  Although this is a useful 
summary of the cost-effectiveness of T1 compared to T0, the key question is whether or not the 
additional 200,000 DALYs averted justify the additional $20mn required.  An estimate of health 
opportunity costs of $200 per DALY is represented by the rising diagonal in Figure 1.  Since every 
$200 of health care resources could be used to avert one DALY, the addition costs of $20mn could, 
instead, have been used to avert 100,000 DALYs elsewhere in the health care system.  
 
The health benefits of 200,000 DALYs averted can be directly compared to the health opportunity 
costs of 100,000 DALYs.  The intervention offers positive net health benefits of 100,000 DALYs 
averted and should be regarded as cost effective because it will improve health outcomes overall.  
Equivalently, the value of the intervention can be expressed as the amount of health care resources 
that would be required to generate the same health benefits elsewhere, e.g. $40mn would be 
required to avert 200,000 DALYs.  The $ value of the intervention to the health care system ($20mn) 
is the difference between the monetary valuation of the additional health benefits ($40mn) and the 
additional costs ($20mn).  Reporting cost-effectiveness in these ways is entirely equivalent to asking 
whether the ICER for alternative T1 is less than a threshold that represents health opportunity costs.  
However, an assessment of health opportunity costs allows the results of cost effectiveness analysis 
to be expressed in ways that can more directly inform prioritisation and development decisions (see 
Section 2.2.2). 
 
An assessment of health opportunity cost is required whether or not additional costs must be found 
from existing resources or from increases in health expenditure that could have been used in other 
ways.  Therefore, an assessment of health opportunity cost that represents what a health care 
system could have delivered with more or less resources (i.e. a supply side estimate of the marginal 
productivity of the health care system, see Section 2.3) is required, whether or not there are explicit 
administrative health care budgets and whether or not there are restrictions on the growth in health 
expenditure.   
 
This is also a key question when considering whether more resources should be devoted to health 
care.  For example, it is not possible to sensibly consider how much should be spent on an activity 
without some assessment of what is likely to be gained from that expenditure.  In the context of 
health care that requires an assessment of the likely productivity of the health care system, i.e. an 
                                                          
1
  Commonly there will be a number of alternative mutually exclusives available including the option of offering no care for 
a specific indication and target population.  The principles illustrated in Figure 1 and Table 1 generalise to a full incremental 
analysis of multiple alternatives, which should not be restricted to existing provision (Drummond et al., 2015), see 
Appendix 2. 
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assessment of what a health care system currently delivers with more or less resources (see Section 
2.3). 
 
Figure 1 Cost-effectiveness and health opportunity costs 
 
ŽŶƐĞƋƵĞŶĐĞƐŽĨĂĚŽƉƚŝŶŐĂ ?ƚŚƌĞƐŚŽůĚ ?ƚŚĂƚŝƐƚŽŽŚŝŐŚ 
dŚĞĐŽŶƐĞƋƵĞŶĐĞƐŽĨƵƐŝŶŐĂ ?ƚŚƌĞƐŚŽůĚ ?ƚŚĂƚŝƐƚŽŽŚŝŐŚƚŽũƵĚŐĞĐŽƐƚ-effectiveness can be illustrated 
in Figure 1. If the costs of the intervention were higher (C2=$60mn), the new technology (T2) would 
offer one DALY averted for every additional $300 spent.  This would be regarded as cost-effective at 
higher thresholds (e.g. at a threshold of $500 per DALY, which might represent GDP per capita). 
However, the health opportunity cost of these additional costs (300,000 DALYs) exceeds the health 
benefits.  Concluding that the intervention is cost-effective, including it in the EHP and/or prioritising 
its implementation, will reduce rather than improve health outcomes overall (a net loss of 100,000 
DALYs).  This illustrates the dangeƌƐŽĨĂĚŽƉƚŝŶŐ ?ƚŚƌĞƐŚŽůĚƐ ?ƚŚĂƚƌĞƉƌĞƐĞŶƚĂƉĂƌƚŝĐƵůĂƌǀŝĞǁŽĨǁŚĂƚ
value ought to be placed on health (see Section 2.5) rather than an assessment of what the health 
opportunity cost are likely to be given the resources currently available (see Section 2.3).   
 
Adopting  ?ƚŚƌĞƐŚŽůĚƐ ?ǁŚŝch are higher than the likely health opportunity cost also underestimates 
the health that could be gained by increasing health care expenditure.  An explicit and evidence 
based assessment of health opportunity costs exposes the implications of the resources currently 
available and the real value of increasing them.  It contributes to greater accountability in low and 
middle, as well as in high-income countries, for the health care and other expenditure decisions 
made at a local, national and supra national levels. 
 
  
Health opportunity cost
$200 per DALY
B $200 
per DALY
$40mnCost = C*
300
DALYs averted (,000)
Additional HCS cost
$300 
per DALY
$60mnCost = C2
$20mn
200
$100 
per DALY
Cost = C1
100
Net DALYs averted
= 100,000
Net DALYs gained 
= 100,000
0
3
1
$ value to HCS
= $20mn
T0
T3
T2
T1
Supporting the development of an essential health package: principles and initial assessment for Malawi  9 
 
Informing purchasing and pricing decisions 
An assessment of health opportunity costs demonstrates that the price paid for a technology is just 
as important as how effective it might be.  In Figure 1, an additional cost of C*=$40mn represents 
the maximum the health care system can afford to pay for the benefit the technology offers (at C* 
the net DALY averted and the $ value to the health care system are zero).  This can inform pricing 
and purchasing decisions by identifying the maximum price that a health care system (HCS) can 
afford to pay for a technology that is protected by patent, e.g. a branded pharmaceutical.  Different 
health care systems are likely to face different health opportunity costs so the maximum, or value 
based, price of a branded pharmaceutical will differ (e.g. it is likely to be much lower in Malawi than 
in South Africa or even in other LICs, such as Mozambique).  This assessment can be used to inform 
evidence based tiered pricing mechanisms, which respect patent protection, and inform value based 
purchasing negotiations.  It also identifies the value of more effective purchasing of other health 
care inputs and the most that might be offered as incentives to encourage implementation, e.g. 
ƚŚƌŽƵŐŚ ?ƉĂǇŵĞŶƚďǇƌĞƐƵůƚƐ ?ŵĞĐŚĂŶŝƐŵƐ ?ƐĞĞSection 2.2.2).   
 
Supporting decision making 
Estimates of the health effects of changes in health care expenditure indicates health effects of 
other care that is likely to be offered if the required increase in expenditure was, instead, made 
available for other uses, or the health likely to be forgone if the additional resources required must 
be found from existing commitments.  It is a measure of the amount of health that a health care 
system currently delivers with more or less resources, i.e. a supply side measure of the marginal 
productivity of health care expenditure (see Section 2.3).    
 
These types of estimates can support decision making by providing a useful benchmark against 
which the likely overall health impact of the range of potential investment and/or disinvestment 
decisions can be judged.  It indicates the health effects of the other investments or disinvestments 
that are likely to be made elsewhere (rather than could be made) when more or fewer resources are 
available.  Such cost-ĞĨĨĞĐƚŝǀĞŶĞƐƐ ?ƚŚƌĞƐŚŽůĚƐ ?ĂƌĞŶŽƚĚĞĐŝƐŝŽŶ ?ƌƵůĞƐ ?ďƵƚƉƌŽǀŝĚĞĂďĞŶĐŚŵĂƌŬƚŽ
search for and explicitly identify other under exploited investments which could offer greater value, 
and existing commitments that could be disinvested to accommodate more valuable ones (the 
resources released could be used to avert more DALYs).  As well as informing the content and scale 
of an EHP, an assessment of health opportunity costs based on estimates of the health effects of 
changes in expenditure can also inform the incremental reallocation of resources which can 
strengthen a health care system and improve health overall.   
 
There are also other constraints, (e.g. skilled labour, budgetary silos, political considerations etc.) 
which may mean that a cost-effective and valuable intervention cannot be fully implemented.  The 
net DALYs averted and the $ value to the HCS indicates the opportunity cost of existing constraints, 
the value of addressing them and how strengthening these aspects of the health care system might 
be prioritised (see Section 2.2.2).  Health and how it is measured (DALYs) is unlikely to be the only 
social objective of health care expenditure (e.g. others might include improving equity etc.).  An 
assessment of health opportunity costs allows the sometimes necessary trade-offs to be identified 
and explicitly considered (e.g. when considering whether to include an intervention in a benefits 
package that might not be judged cost-effective but would offer significant benefits to 
disadvantaged groups). 
 
A cost-effectiveness threshold based on an assessment of the likely health opportunity costs makes 
it clear that health care costs matter because they represent the opportunity to improve the health 
of others who could benefit from health care.  Although the direct beneficiaries of an intervention 
might be more readily identifiable compared to those who will ultimately bear the health 
opportunity costs, there appears to be no reason to treat those who are more easily identifiable 
differently from those who are not.  An empirical assessment of health opportunity costs makes the 
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strong ethical foundation of cost-effectiveness analysis less abstract and more easily communicated 
to the range of stakeholders.  This can help make the politically difficult decisions of what 
programmes and interventions can be include in the EHP (and which cannot) a more accountable, 
evidence based and, therefore, sustainable prospect. 
 
2.2.2 Prioritising implementation 
An assessment of health opportunity costs makes it possible to express cost-effectiveness as the 
expected additional net health or net monetary benefit offered.  This provides much more useful 
information than a categorical assessment of whether or not an intervention is cost-effective (see 
Appendix 2)2.  It indicates the scale of the potential overall impact of ensuring an intervention is fully 
implemented and identifies the amount of resource that might be devoted to these efforts.  
 
For example, in Figure 1 and in Table 1 an intervention T1 with costs of C1=$20mn would be 
regarded as cost-effective. Its full implementation would offer substantial net health benefits of 
100,000 DALYs averted so it might be prioritised for additional implementation efforts.  The $ value 
to the HCS of $20mn indicates an upper bound on the resources that might be devoted to this; for 
example, by addressing constraints which might not be fully reflected in the costs (e.g. labour 
constraints) or aspects of health system strengthening that might be required.  An intervention T2 
offering the same health benefits but with additional costs of C*=$40mn might also be judged to be 
cost-ĞĨĨĞĐƚŝǀĞ ?ƚŚĞĐŽƐƚƉĞƌ>zŽĨ ? ? ? ?ŝƐĞƋƵĂůƚŽƚŚĞ ?ƚŚƌĞƐŚŽůĚ ? ? ?,ŽǁĞǀĞƌ ?ƚŚĞŚĞĂůƚŚ
opportunity costs of 200,000 DALYs are equal to the additional health benefits it offers.  Its full 
implementation will neither improve nor reduce health outcomes overall (net DALYs averted are 
zero) so it should not be prioritised because any additional resources required would reduce health 
outcomes overall. 
 
Table 1 Prioritising implementation efforts 
Technology 
ICER 
($/DALY) 
DALYs averted 
(,000 DALYs) 
HCS 
Costs 
Net DALYS averted 
(,000 DALYs) 
$ Value to 
 HCS 
T3 $300 200 $60m -100 -$20m 
T2 $200 200 $40m 0 0 
T1 $100 200 $20m 100 $20m 
T4 -$100 200 -$20m 300 $60m 
 
Interventions which save health care costs can be judged and prioritised in the same way, rather 
than simply categorising them as cost-effective.  For example, an intervention (T4 in Table 1) that 
offered the same health benefits but also saved $20mn of health care costs would have greater 
value because the saved resources would be available for other health care activities. These would 
ďĞĞǆƉĞĐƚĞĚƚŽĂǀĞƌƚ ? ? ? ? ? ? ?>zƐĞůƐĞǁŚĞƌĞ ?ŝ ?Ğ ?ƚŚĞƌĞĂƌĞŚĞĂůƚŚŽƉƉŽƌƚƵŶŝƚǇ ?ŐĂŝŶƐ ?ƌĂƚŚĞƌƚŚĂŶ
costs).  The net DALYs averted would be greater (300,000 DALYs averted) because they include the 
ĂĚĚŝƚŝŽŶĂůďĞŶĞĨŝƚŽĨƚŚĞƚĞĐŚŶŽůŽŐǇ ? ? ? ? ? ? ? ?>zƐĂǀĞƌƚĞĚ ?ƉůƵƐƚŚĞŚĞĂůƚŚŽƉƉŽƌƚƵŶŝƚǇ ?ŐĂŝŶƐ ?
(100,000 DALYs averted)3.  Similarly the $ value to the HCS is greater ($60mn) because it includes the 
amount of health care resources that would be required to generate the same health benefits 
elsewhere ($40mn), plus the saving of $20mn.   
 
An assessment of net DALYs averted and the $ value to HCS enables prioritisation of implementation 
efforts among those interventions which are cost saving.  It also ensures that all interventions, 
                                                          
2
  Cost per DALY measures cannot be used to rank interventions by the value they offer or indicate the scale of value (in 
DALYs or $).  Therefore, cost per DALY cannot be used to prioritise implementation efforts.  The examples of technologies 
T1  WT4 in Table 1 are a simple special case where the scales of population health benefits are the same.  See Appendix 2 for 
examples where cost-per DALY is especially misleading because the population that can benefit from each technology 
differs. 
3
  This can also be represented graphically in the south west quadrant of Figure 1. 
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whether cost saving or not, are prioritised in the same way based on the scale of the impact on 
overall health outcomes.  This is especially important because the value (in DALYs averted or $) of 
interventions which require additional health care resources can be greater than those that save 
costs.  Similarly, an intervention with an ICER that is higher than others may offer greater net DALYs 
averted or $ value to HCS so might be a higher priority for implementation efforts.  An assessment of 
health opportunity costs makes it possible to estimate the scale of the potential impacts on overall 
health outcomes of implementation efforts in a way that reporting ICERs and categorical judgments 
about cost-effectiveness do not (see Appendix 2)4. 
 
2.3 Estimating health opportunity costs 
The problem of estimating a cost-effectiveness threshold that represents expected health 
opportunity costs is the same as estimating the relationship between changes in health care 
expenditure and health outcome.  This is the approach that was taken in research conducted in the 
UK. 
 
2.3.1 Recent estimates for the United Kingdom 
This research used national data on expenditure and outcomes in different areas of disease 
(programme budget categories) reported at a local level in the UK NHS (Claxton et al., 2015a) 
(Martin, Rice and Smith, 2008).  By exploiting the variation in expenditure and mortality outcomes, 
the relationship between changes in spending and mortality was estimated while accounting for 
endogeneity5.  With additional information about age and gender of the patient population, the 
estimated mortality effects were expressed as survival effects (£25,241 per life year) which were 
adjusted for health related quality of life.  By using the effect of expenditure on the mortality and 
life-year burden of disease as a surrogate for the effects on a more complete measure of burden 
(one that also includes the quality of life burden of disease), a cost per QALY threshold that reflects 
the likely impact of expenditure on both mortality and morbidity was estimated (£12,936 per QALY). 
 
This cost per QALY threshold is founded on estimating the health effects of changes in expenditure 
in 23 different disease areas (groups of ICD codes).  Therefore, as well as identifying the scale of 
health opportunity costs, it also indicates how they are likely to be made up including the type of 
health effects (e.g. mortality, survival and morbidity), and where these are likely to occur (e.g. which 
disease areas and by age and gender).  As a consequence, it is also possible to estimate the severity 
of disease associated with the health opportunity costs, how they are likely to be distributed, and 
the impact of changes in expenditure on health inequality (Claxton et al., 2015b) (Love-Koh et al., 
2016).   
 
Other work by the UK Department of Health estimated the net production effects for the wider 
economy of changes in length and quality of life by age, gender, and type of disease.  This enabled 
the net production impact of changes in health expenditure (including marketed and non-marketed 
activities) to be estimated (Claxton et al., 2015b).  More recent work has explored the impact of the 
scale of changes in expenditure on health outcomes, i.e. how the scale of budget impact and 
questions of affordability effect health opportunity costs.  The UK Department of Health is 
supporting the ongoing re-estimation of cost per QALY thresholds for subsequent waves of data, 
which will provide a time series of estimates.  
                                                          
4
  When there is more than one active intervention available within a programme (a specific indication for a specific 
population) the use of cost per DALY is even more problematic. An assessment of health opportunity costs which enables 
measures of the net DALYs averted and $ value to HCS overcomes these difficulties (see Appendix 2). 
5
  Health outcomes in a particular disease area are influenced by expenditure (increases in expenditure improves 
outcomes), but outcomes also influence expenditure (poor outcomes prompt greater efforts and increased expenditure). 
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2.3.2 Possible implications for other countries 
The research conducted in the UK represents the first estimate of what a health care system 
currently delivers with more or fewer resources given the scale of total health care expenditure, i.e. 
a supply side estimate of its marginal productivity.  It reveals how much the UK health care system 
can afford to pay to improve health given how much of available national income has been devoted 
to health care e.g. £12,936 per QALY in 2008/09 represented 48% of UK GDP pc.   
 
Woods et al. (2015) explores the possible implications that this might have for other countries with 
different incomes.  Published research has explored how the value placed on improvements in 
health vary with income, based on how much consumption individuals are willing to give up to 
reduce mortality risk from cross sectional and longitudinal studies.  A smaller literature has 
examined how these estimates of income elasticity of demand might be applied across countries.  
Insofar as what heath care systems can deliver (the supply side) is consistently related to measures 
of the consumption value of health (an indication of the demand for health), estimates of income 
elasticity can be used to extrapolate the estimates reported in Claxton et al. (2015b) to other 
countries.  
 
In general, the range of estimates of income elasticity suggests that a greater proportion of income 
is likely to be devoted to health care as income rises.  This suggests that cost-effectiveness 
thresholds for countries with substantially less income than the UK are unlikely to be greater than 
48% of GDP pc.  For example, the range of estimates for Ethiopia, a country with a GDP pc of $505, is 
$10-$255 per QALY, or 2%-50% of GDP pc; and for Indonesia, with a GDP pc of $3,457, it is $472-
$1,786 per QALY, or 14%-51% GDP pc (all in 2013 US$). 
 
These ranges do not reflect all sources of uncertainty.  For example, there is uncertainty associated 
with the UK estimate of £12,936 per QALY, and the alternative estimates of income elasticity are 
based on the value of reducing mortality risk rather than improvements in survival and reductions in 
morbidity6 ?/ŵƉŽƌƚĂŶƚůǇ ?ŚŽǁĞǀĞƌ ?ŝƚŵƵƐƚĂůƐŽďĞĂƐƐƵŵĞĚƚŚĂƚĂŶǇƉƌŽƉŽƌƚŝŽŶĂƚĞ ?ƵŶĚĞƌĨƵŶĚŝŶŐ ?ŽĨ
health care from collectively pooled resources, compared to individual preferences about health and 
consumption, is similar across countries, i.e. the supply side of health care systems are related to 
measures of the demand for health in a similar and consistent way.  The difficulties faced in 
financing health care systems in low income countries are well documented and suggests that 
 ?ƵŶĚĞƌĨƵŶĚŝŶŐ ?ŝƐůŝŬĞůǇƚŽďĞƉƌŽƉŽƌƚŝŽŶĂƚĞůǇŐƌĞĂƚĞƌ ?ƐŽĐŽƐƚ-effectiveness thresholds are likely to 
be lower in these settings.  However, where donor funding represents a significant component of 
ŚĞĂůƚŚĞǆƉĞŶĚŝƚƵƌĞ ?ĂŶĚĂŶǇƐƵďƐƚŝƚƵƚŝŽŶĞĨĨĞĐƚƐĂƌĞƉĂƌƚŝĂů ?ƚŚĞŶƚŚĞƉƌŽƉŽƌƚŝŽŶĂů ?ƵŶĚĞƌĨƵŶĚŝŶŐ ?
maybe be offset by this assistance and the cost-effectiveness threshold may be higher.   
 
Although the estimates reported in Woods et al. (2015) are based on limited data and uncertain 
assumptions, it is not clear a priori whether these are likely to lead to over- or under-estimates of 
thresholds that represent the likely health opportunity costs in LMICs.  They do, however, provide 
indicative estimates which attempt to draw out the possible implications of the limited evidence 
that is available. 
 
2.3.3 Estimates of the effect of expenditure on mortality outcomes 
The effect of different levels of health care expenditure on mortality outcomes has been 
investigated in a number of published studies using aggregate country level data (Nakamura et al., 
2016).  The challenge is to control for all other reasons why mortality might differ between countries 
                                                          
6
  The morbidity adjusted survival effects of changes in mortality risk are likely to vary across countries with different GDP 
pc.  Where the morbidity adjusted survival effects of changes in mortality are believed to be lower, the cost per QALY 
threshold will be higher.  Although life expectancies tend to be lower in lower income settings, mortality tends to occur at 
younger ages so the net effect on cost per QALY thresholds is unclear. 
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to isolate the causal effect of differences in health expenditure.  This is a particular challenge even if 
available measures are complete, accurate and unbiased because health expenditure and other key 
variables (e.g. GDP pc) are likely to be endogenous7.  A number of published studies have used 
instrumental variables to overcome this problem and identify the mortality effect of different levels 
of health expenditure.     
 
For example, Bokhari, Gai and Gottret (2007) apply this approach to a cross-section of 127 countries 
to estimate the proportionate effect (on maternal and under 5 mortality) of proportionate changes 
in health expenditure (they estimate elasticities).  They account for the endogeneity of public health 
expenditure and GDP per capita, and also allow changes in donor funding and measures of 
infrastructure to influence the mortality effects of expenditure.  In their re-evaluation of this 
analysis, Nakamura et al. (2016) find that while the estimates are somewhat sensitive in magnitude, 
qualitatively the model estimates are robust.   
 
Ochalek et al. (2015) demonstrate how these types of estimates can be extended to include the 
likely impact on length and quality of life (measuƌĞĚďǇ>zƐ ? ?ƌĞĨůĞĐƚŝŶŐĂĐŽƵŶƚƌǇ ?ƐĚĞŵŽŐƌĂƉŚǇ ?
epidemiology, level of health care expenditure, income and other characteristics.  For example, 
Bokhari et al. (2007) can be extended to estimate the effect of expenditure on adult male and 
female mortality.  The estimated elasticities can be expressed as a cost per life year gained using 
country specific estimates of mortality rates, conditional life expectancies and population (all by age 
and gender), as well as the level of total health expenditure.  These country specific estimates of cost 
per life year can be expressed as a cost per DALY averted based on estimates of morbidity (years of 
life with disability) and assuming that the mortality effects of expenditure is a reasonable surrogate 
ĨŽƌƚŚĞůŝŬĞůǇŵŽƌďŝĚŝƚǇĞĨĨĞĐƚƐ ?dŚĞƐĞ ?ŝŶĚŝƌĞĐƚ ?ĞƐƚŝŵĂƚĞƐŽĨƚŚĞĐŽƐƚƉĞƌ>zƵƐĞŽƚŚĞƌĚĂƚĂĂŶĚ
explicit assumptions to link directly estimated mortality effects to survival and morbidity (in a similar 
way to the analysis in Claxton et al. (2015a)).  Ochalek et al. (2015) are also able to directly estimate 
survival effects, disability effects and DALY effects of changes in expenditure by re-estimating the 
statistical model using data on years of life lost (YLL), years of life with disability (YLD) and DALYs for 
each country. 
 
Ochalek et al. (2015) provide a number of cost per DALY estimates for each country, which enables a 
comparison of indirectly estimated effects on survival and disability (e.g. when only mortality data is 
available) to directly estimated effects on DALYs.  In general, estimating DALY effects indirectly from 
changes in mortality does not necessarily lead to over or underestimation of cost per DALY averted.  
This suggests the framework of analysis set out in Ochalek et al. (2015) can be applied to the results 
of any econometric study thought to identify plausible effects on mortality of changes or differences 
in health expenditure.  The difficultly is identifying effects of health expenditure on mortality using 
aggregate country level data given the challenges of endogeneity, limited and sometimes weak 
instruments, missing data and measurement error (Nakamura et al., 2016). 
 
2.3.4 Summary of evidence for cost per DALY thresholds 
The estimates reported in Woods et al. (2015) and Ochalek et al. (2015) show how existing evidence 
of the effect of changes in health expenditure on health outcomes can be marshalled to inform an 
assessment of health opportunity costs in LMICs.  The range of estimates of a cost per DALY for each 
LMIC8 based on Woods et al. (2015) and Ochalek et al. (2015) are reported in Figure 2 by GDP pc.  
The ranges from these two different sources are, in broad terms, reasonably consistent.  They 
suggest that the cost per DALY is typically lower in lower income settings (health opportunity costs 
are typically higher) and are very likely to be lower than one GDP pc. 
 
                                                          
7
  See Footnote 5. 
8
  Countries that were classified as a LMIC in 2000. 
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The range of estimates of cost per DALY thresholds for each country is reported in Figure 3 by under 
5 mortality rates.  As expected the cost per DALY is likely to be lower for countries with higher under 
5 mortality, so increases in expenditure in these contexts are likely have greater health effects.  This 
relationship does not simply reflect any negative correlation between under 5 mortality and GDP 
pc9, but reflects different absolute effects of changes in expenditure in countries with different 
baseline mortality rates, demographics and total health care expenditure, as well as different 
relative effects in countries with different levels of infrastructure and donor funding. 
 
Although the estimates from Woods et al. (2015) and Ochalek et al. (2015) rest on a number of 
assumptions and judgements, including the robustness of different underpinning research (e.g. 
Claxton et al. (2015a) and Bokhari et al. (2007) respectively), they both indicate broadly similar 
implications of the balance of existing evidence.  In particular, they suggest that the type of GDP pc 
based thresholds that have become widely used to judge cost-effectiveness in LMICs (see Section 
3.2) are likely to be significantly higher than an assessment of health opportunity costs, e.g.  the cost 
per DALY may be less than half GDP pc for most health care systems.  However, the results from 
Ochalek et al. (2015) also suggests that expressing cost per DALY in terms of GDP pc might not be the 
best way to summarise how health opportunity costs are likely to differ between countries.  GDP pc 
is clearly important but mortality rates, demographics, total health care expenditure, as well as 
donor funding and infrastructure, are also important.  Rather than adopting a simple summary, 
based only on GPD pc, Ochalek et al. (2015) show that country specific estimates, which reflect the 
interaction of all these factors, are possible. 
 
 
Figure 2 Cost per DALY ranges for Woods et al. (2015) and Ochalek et al. (2015) by GDP pc 
                                                          
9
  The estimates from Woods, B., et al. (2015) would simply reflect any negative correlation of under 5 mortality and GDP 
pc, so have been excluded from this figure. 
Supporting the development of an essential health package: principles and initial assessment for Malawi  15 
 
 
Figure 3 Cost per DALY ranges from Ochalek et al. (2015) by under 5 mortality 
 
Any empirical approach to estimating the effect of health expenditure on health outcomes is 
especially challenging when using aggregate and routinely reported country level data.  The re-
analysis of Bokhari et al. (2007), and Moreno-Serra and Smith (2015) by Nakamura et al. (2016) 
highlights some of the difficulties including: measurement error (which tends to bias estimates 
downwards and reduce statistical significance); missing data and the implications of imputation; as 
well as potentially weak instruments.  Better quality and more complete data at country level, as 
well as finer data at household level, might overcome some of these problems.  Estimates based on 
within country data may be feasible in some LMICs, especially where it is possible to exploit 
exogenous changes (natural experiments) such as increased public insurance coverage, or where 
data are available from large scale field experiments which involve changes in health care resources.  
Whatever the empirical challenges might be, some implicit assessment of health opportunity costs is 
unavoidable.  The range of indicative estimates from Woods et al. (2015) and Ochalek et al. (2015) 
may provide a useful starting point for its explicit assessment and a process of refinement. 
 
2.4 What are the implications for Malawi? 
This evidence suggest that health opportunity costs are likely to be substantially higher (cost per 
DALY lower) than suggested by global and national bodies that make recommendations about cost-
effectiveness (see Section 2.5).  This suggests that health care expenditure is more productive and 
can have a greater impact on health than the implied values and widely cited norms (see Section 
2.5).  The qualitative implication of this evidence appears to be consistent across all health care 
systems, but it is especially so for health care systems in low-income countries.  Figure 4 expresses 
the estimates of cost per DALY as a % of GDP pc for all low income countries.  It suggests that a cost 
per DALY that reflects the likely health opportunity costs is almost certain to be lower than 50% of 
GDP pc and probably significantly lower. 
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Figure 4 Cost per DALY ranges as % GDP pc for low-income countries 
 
For the reasons set out in Section 2.3 the estimates from Ochalek et al. (2015) may be regarded as 
the most plausible, because they use more of the evidence that is currently available including: the 
effects of health expenditure (elasticities) while taking account of country specific measures of 
infrastructure, donor funding, population (age and gender), mortality rates (age and gender), 
conditional life expectancies (age and gender) and total health care expenditure.  Although the re-
estimated elasticities based on Bokhari et al. (2007) represent one of the better approaches to 
statistical estimation, there are over 60 other published papers in this area; some of which estimate 
smaller effects (in part because some do not account for endogeneity).  A recent but unpublished 
meta-regression suggests that elasticities might be lower if account is taken of all these other 
published papers.  On the other hand, the effects of aggregation (due to using country level data and 
all-cause mortality) are likely to underestimate the effects.  On balance, we believe it would be best 
to regard the upper bound from Ochalek et al. (2015) as a plausible lower bound for health 
opportunity cost in Malawi and the upper bound from Woods et al. (2015) as an extreme upper 
bound (see Table 2). 
 
Table 2 Estimates of health opportunity costs for Malawi 
 Lower estimate Upper estimate 
 $ per DALY % GDP pc $ per DALY % GDP pc 
Woods et al. (2015) $3 1% $116 51% 
Ochalek et al. (2015) $24 11% $37 16% 
 
The range of cost per DALY estimates reported in Table 2 that represent health opportunity costs in 
Malawi can be used to consider which programmes and interventions might be included in an EHP, 
what the scale of the EHP might be and how efforts to implement interventions might be prioritised.  
It also allows the health opportunity costs of the other constraints that decision makers face 
(including restrictions placed on assistance by donors) to be identified.  These assessments can be 
used to prioritise aspects of health care system strengthening and negotiate more effectively with 
ĚŽŶŽƌƐŽŶŚŽǁƚŚĞŝƌĂƐƐŝƐƚĂŶĐĞĐĂŶďĞƐƚŵĞĞƚDĂůĂǁŝ ?ƐŚĞĂůƚŚĐĂƌĞŶĞĞĚƐ ? 
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An assessment of health opportunity costs that represents what a health care system could have 
delivered with more or less resources (i.e. the supply side estimate of the marginal productivity of 
the health care system) is required whether or not there are explicit administrative health care 
budgets and whether or not there are restrictions on the growth in health expenditure.  It is also a 
key question when considering whether more resources should be devoted to health care. It is not 
possible to consider sensibly how much should be spent on an activity without some assessment of 
what is likely to be gained from that expenditure.  In the context of health care that requires an 
assessment of the health effects of health care expenditure, i.e. an assessment of health opportunity 
costs that represents what a health care system could have delivered with more or less resources.  
For example, the estimates of health opportunity costs in Table 2 indicate what the current evidence 
suggests Malawi is currently paying to avert a DALY.  When this is combined with information about 
the health programmes and interventions that are available this also indicates the possible scale 
(total budget) of the EHP (see Section 3).  This estimate might be regarded as too low if many 
Malawians would wish to pay more to avert a DALY.  Higher estimates, such as $60 or $116 per 
DALY, imply an expanded EHP with a larger budget.  Once the health that is likely to be delivered by 
greater health care expenditure is set out it then becomes possible to have a more meaningful 
ĚĞůŝďĞƌĂƚŝŽŶĂďŽƵƚŚŽǁDĂůĂǁŝ ?ƐƉƵďlic finance resources might be allocated between competing 
claims (health education, infrastructure etc.) and how increases in public finance might be achieved. 
 
2.5 Other suggested thresholds 
Much of the published literature and the values recommended or cited by decision making and 
advisory bodies (both national and supra national), reflect a lack of conceptual clarity about what a 
cost-effectiveness threshold ought to represent and what type of evidence might inform its 
assessment (Revill et al., 2014) (Culyer, 2015).  This lack of clarity rests on a failure to distinguish 
clearly three very different notions of what a cost-effectiveness threshold should represent:  
 
i) An assessment of health opportunity costs based on evidence of the health effects of changes in 
health care expenditure i.e. a measure of the amount of health that a health care system 
currently delivers with more or less resources (a supply side measure of the marginal 
productivity of health care expenditure, see Section 2.1 and 2.3 above).    
 
ii) Established norms, whether explicit or implied values, that simply describe how cost-
effectiveness is judged and decisions tend to be made (see below). 
 
iii) The value that ought to be placed on improvements in health.  Such values reflect a particular 
view of what constitutes the social value of health.  They imply what the demand for health and 
health care expenditure ought to be, rather than an evidence based assessment of the health 
effects of changes in actual levels of health care expenditure (see below). 
 
2.5.1 Norms and implied values 
An implicit or explicit assessment of health opportunity costs is unavoidable because all decisions 
about health care imply one.  A few health care systems have revealed something about the type of 
threshold values likely to be used when making decisions (Vallejo-Torres et al., 2016).  However, 
reimbursement agencies in only two health care systems have been explicit about the threshold 
used to judge cost-effectiveness, although others seem likely to follow10.  For example, since 2004, 
                                                          
10
  A commission which considered whether Norway should adopt an explicit threshold has recommended research similar 
to that conducted in the UK.  In the meantime an explicit threshold based on a similar analysis to Woods et al. (2015), is to 
be adopted until a Norwegian within country estimate is available.  Informally, Portugal has amended its implicit threshold, 
which also appears to be based on a similar analysis to Woods et al. (2015). Other HICs (e.g. Spain, Australia and 
Netherlands) have already commissioned within country research, and Canada is considering federally funded research to 
estimate health opportunity costs supported by two of its provincial health care systems. 
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the National Institute for Health and Care Excellence (NICE), which issues guidance to the UK NHS, 
has published an explicit range for the cost-effectiveness thresholds used in its deliberative decision 
making process (£20,000 to £30,000 per QALY).  Although NICE makes clear that the threshold ought 
to represent the health consequences of additional NHS costs, this range was founded on the values 
implied by the decisions it made between 1999 and 2003 (Rawlins and Culyer, 2004).  The NICE 
thresholds are implied values from previous decisions and have been widely recognised for some 
time (including by NICE) as having little empirical foundation11.  This range has become an 
established norm, which is intended to represent how NICE makes its decisions12  rather than an 
empirical assessment of the likely health opportunity costs.  Other established norms are also 
evident in published economic evaluations.  For example, in the US, threshold of $50,000 to 
$100,000 per QALY have become increasingly cited but are widely recognised as having little 
evidential foundation (Neumann, Cohen and Weinstein, 2014). 
 
2.5.2 The value of health 
Other suggested thresholds reflect how much consumption should be given up to improve health.  
They represent a view of what the demand for health and health care expenditure ought to be, 
rather than an assessment of the health effects of changes in actual health care expenditure, i.e. a 
 ?ƐƵƉƉůǇƐŝĚĞ ?ĂƐƐĞƐƐŵĞŶƚŽĨŚĞĂůƚŚŽƉƉŽƌƚƵŶŝƚǇĐŽƐƚƐ ? 
 
Thresholds that reflect a view of the demand for health have been expressed in two subtly different 
ways: aspirational ones, which represent a particular view of what value ought to be placed on 
health improvements and how much resources should be devoted to health care; and those based 
on evidence of how much consumption individuals are willing to give up to improve their health.  
There is a large literature which has used stated preferences (hypothetical valuations) to estimate 
the consumption value or willingness to pay for a QALY.  Most estimate how much consumption an 
individual is willing to give up to improve their own health.  A few try to elicit how much individuals 
believe society should pay to improve health more generally.  A wider literature, that extends 
beyond health, estimates the value of a statistical life, based on how much consumption individuals 
are willing to give up to reduce their mortality risk.  Some studies are based on stated preferences 
(hypothetical choices) but others identify situations where individuals actually make choices that 
imply a value, e.g. revealed preferences in the labour market.  A cost per QALY or cost per DALY can 
be derived from these studies by making assumptions about age and gender distribution, conditional 
life expectancies and quality of life norms.   
 
Recent reviews of this literature (Vallejo-Torres et al. (2016) and Ryen and Svensson (2014)) reveal 
very wide variation in values, even within countries.  However, some patterns do emerge.  Reported 
values are generally lower than the type of GDP pc based thresholds that have become widely used 
ŝŶ>D/Ɛ ?ďƵƚƚĞŶĚƚŽďĞŚŝŐŚĞƌƚŚĂŶĂǀĂŝůĂďůĞĞƐƚŝŵĂƚĞƐŽĨĂ ?ƐƵƉƉůǇƐŝĚĞ ?ĂƐƐĞƐƐŵĞŶƚŽĨŚĞĂůƚŚ
opportunity costs.  This suggests a discrepancy between the demand and supply side of health care 
systems.  For example, if the type of individual preferences expressed in these studies are regarded 
as an appropriate expression of social value, the difference would indicate that health care from 
ĐŽůůĞĐƚŝǀĞůǇƉŽŽůĞĚƌĞƐŽƵƌĐĞƐŝƐ ?ƵŶĚĞƌĨƵŶĚĞĚ ?ĐŽŵƉĂƌĞĚƚŽŝŶĚŝǀŝĚƵĂůƉƌĞĨĞƌĞŶĐĞƐĂďŽƵƚŚĞĂůƚŚĂŶĚ
consumption.  However, given the difficulties faced in the public financing of health care systems in 
high income countries as well as LMICs this is what might be expected.  
 
                                                          
11
  The House of Commons investigation of NICE in 2008 identified that the thresholds used by NICE had little empirical 
foundation.  In response, NICE commissioned Appleby et al. (2009), and asked UK research funders to commission the 
research that was published in Claxton et al. (2015a). 
12
  NICE does not reject technologies with ICERs less than its stated upper bound of £30,000 per QALY.  Current evidence 
suggests that the thresholds implied by NICE decisions are, in fact, much higher (£39,417 to £43,949 per QALY, (Dakin et 
al., 2014) even when special considerations do not apply. 
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However, values based on individual preferences about health and consumption reflects a particular, 
but quite reasonably disputed, view of what might constitute the social value of health (Drummond 
et al., 2015).  Even if this important and difficult question of social value was not disputed, the 
estimates imply what health expenditure ought to be rather than reflecting the implications of what 
ŚĞĂůƚŚĞǆƉĞŶĚŝƚƵƌĞĂĐƚƵĂůůǇŝƐ ?^ŝŶĐĞ ?ĚĞŵĂŶĚƐŝĚĞ ?ǀĂůƵĞƐ ?ĞƐƉĞĐŝĂůůǇĂƐƉŝƌĂƚŝŽŶĂůŽŶĞƐ ?ĂƌĞůŝŬĞůǇƚŽ
be substantially higher than an assessment of the actual health opportunity costs (the supply side) 
their use is likely to reduce overall population health and underestimate the real value of devoting 
more resources to health care (see Section 2.1).   
 
Some agencies have adopted or recommended explicit thresholds informed by these types of 
 ?ĚĞŵĂŶĚƐŝĚĞ ?ĞƐƚŝŵĂƚĞƐ ?&ŽƌĞǆĂŵƉůĞ ?ŝŶ ? ? ? ?ƚŚĞtŽƌůĚ,ĞĂůƚŚKƌŐĂŶŝǌĂƚŝŽŶƌĞĐŽŵŵĞŶĚĞĚ
explicit cost per DALY thresholds to serve as a guide alongside WHO-CHOICE. They have been used 
as generic and internationally applicable criteria to classify interventions as highly cost-effective (less 
than one GDP pc), cost-effective (less than three GDP pc) or not cost-effective (three GDP pc or 
higher).  They appear to have been based on estimates of the value of a statistical life reported in 
the Commission on Macroeconomics and Health 2001.  Despite the widely recognised shortcomings 
of these GDP pc based thresholds (Newall, Jit and Hutubessy, 2014) (Marseille et al., 2015), they 
have nonetheless become established norms, which are widely cited in published economic 
evaluations, have informed recommendations made by agencies and, in the absence of other 
country specific estimates, have been commonly used as a criteria to judge cost-effectiveness in 
LMICs.  The current evidence suggests these established norms are aspirational and substantially 
ŚŝŐŚĞƌƚŚĂŶĂǀĂŝůĂďůĞĞƐƚŝŵĂƚĞƐŽĨĂ ?ƐƵƉƉůǇƐŝĚĞ ?ĞƐƚŝŵĂƚĞŽĨŚĞĂůƚŚŽƉƉŽƌƚƵŶŝƚǇĐŽƐƚƐ ?dŚĞǇĂůƐŽ
ĂƉƉĞĂƌƚŽďĞŚŝŐŚĞƌƚŚĂŶŽƚŚĞƌ ?ĚĞŵĂŶĚƐŝĚĞ ?ǀĂůƵĞƐďĂƐĞĚŽŶŝŶĚŝǀŝĚƵĂůƉƌĞĨĞƌĞŶĐĞƐĂďŽƵƚŚĞĂůƚŚ
and consumption. 
 
The only agency in an LMIC that has adopted an explicit evidence based country specific threshold is 
the Health Intervention and Technology Assessment Program (HITAP) in Thailand.  HITAP was 
established in 2007 and adopted threshold based estimates of individual stated preferences about 
health and consumption.  The values were intended to reflect the social value of health in Thailand 
(Jirawattanapisal et al., 2009).  Based on this research, the Health Economic Working Group under 
the Subcommittee for Development of the National List of Essential Drugs and the Subcommittee for 
Development of the Health Benefit Package and Service Delivery of the NHSO recommended a 
threshold of one GDP pc (120,000 THB per QALY).  The organisation has continued to evolve and 
conduct research to inform this issue, raising the threshold to 160,000 THB per QALY in 2013 
(Thavorncharoensap et al., 2013) (Nimdet and Ngorsuraches, 2015).  These thresholds are country 
specific and empirically based estimates but represent a social value of health relative to other 
consumption opportunities rather than a  ?ƐƵƉƉůǇƐŝĚĞ ?ĂƐƐĞƐƐŵĞŶƚŽĨŚĞĂůƚŚŽƉƉŽƌƚƵŶŝƚǇĐŽƐƚƐ ?ďĂƐĞĚ
on evidence of the health effects of changes in actual health care expenditure.  
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3. Supporting the development of an Essential Health Package for Malawi 
3.1 Introduction 
The principles that should shape an analytical framework to guide intervention selection for the EHP 
in Malawi are set out in Section 1, and the rationale for the centrality of health opportunity costs in 
that framework are considered in Section 2.  In this section the framework is developed and 
illustrated, and its implications for the EHP are considered.  As described in Section 1, the framework 
needs to assess how much Malawi can afford to devote to the EHP given how much it currently 
spends on improving population health and what this implies for an EHP budget.  The framework 
should prioritise interventions on the basis of the health benefits they offer the Malawian 
population taking account of health opportunity costs - the health outcomes that could be achieved 
by the health system more generally.  The analytical starting point for the framework should be to 
reflect realistic implementation rates of each intervention reflecting the supply and demand side 
constraints that inevitably exist in getting interventions to in-need populations.  This provides a 
means of quantifying implementation gaps and their implications for reductions in population 
health.  This can show the potential benefits of implementation activities relating to specific 
interventions and of system strengthening more generally.  The framework should also offer a 
means of assessing the impact on population health of the constraints imposed by donors and, as 
such, provide a means of communicating to donors and other stakeholders about the potential 
health benefits of relaxing or reconfiguring those constraints. 
 
In developing this framework, a range of evidence is drawn upon.  Table 3 provides a brief summary 
of the key sources of evidence, and more details are available in Appendix 3.  The best data currently 
available has been brought together, but this can be improved upon and extended over time (see 
Section 4).  The main purpose of the report is to show the principles of the analytical framework, 
how it can guide a range of important policy questions and its implications for the EHP based on 
currently available evidence. 
 
Table 3 Summary of evidence sources; full data available for 67 interventions 
Type of evidence Sources 
Estimates of cost-effectiveness Papers found through Tufts Cost-Effectiveness Analysis registry and 
WHO-CHOICE analyses 
DALYs averted Calculated or taken directly from papers found through Tufts Cost-
Effectiveness Analysis registry and WHO-CHOICE analyses 
Per patient costs (drugs and supplies) EHP HSSPII midterm costing (CMST; EPI/GAVI; unlisted) 
Estimates of realistic coverage levels Bottleneck analysis from the EHP HSSPII midterm costing v87 
Cases (patients) EHP HSSPII midterm costing (EmOC report; MNH Roadmap; Malaria 
Indicator Survey; Malaria costing; etc.) 
Health opportunity costs Woods et al., (In press); Ochalek et al. (2015) 
EHP  W Essential Health Package; HSSPII  W Second Health Sector Strategic Plan II; WHO-CHOICE  W CHOosing Interventions 
that are Cost-Effective  
 
3.2 The appropriate scale of the Essential Health Package 
The analytical framework starts by considering the scale of the EHP  W that is, the appropriate level of 
financial resources that should be devoted to the package.  To address this question it is necessary 
to know something about what Malawi currently gets from its public health expenditure in terms of 
health benefits.  This indicates how much Malawi is currently able to afford for health care and 
provides a means of identifying candidate interventions for the EHP that are expected to generate 
health at a cost that is consistent with what Malawi can afford.  The cost of these candidate 
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interventions provides information on the size of the budget that might reasonably be devoted to 
the EHP.13 
 
As described in Section 2, an empirical estimate of health opportunity costs is central to 
understanding what Malawi is currently able to afford to devote to public health care.  Health 
opportunity costs are expressed in terms of the rate at which the Malawian health care system is 
currently able to translate health care expenditure into improving population health.  The 
framework characterises health in terms of disability-adjusted life years (DALYs) averted (Salomon et 
al., 2012), so health opportunity costs are expressed as the cost per DALY averted in (US $).  As 
discussed in Section 2, the evidence available on health opportunity costs in particular countries 
remains limited.   
 
Two studies provide initial estimates of health opportunity costs for low- and middle-income 
countries, together with appropriate ranges of uncertainty.  The first uses UK estimates of health 
opportunity costs which are extrapolated to other jurisdictions based on the relationship between 
health opportunity costs and the value of health in terms of forgone consumption, and how the 
latter varies with national income levels (Woods et al., In press).  The second uses available cross-
country evidence of the impact of health expenditure on mortality and relates this to DALYs averted 
and how these are impacted by changes in health expenditure for countries with different 
demography, epidemiology, levels of expenditure on health care, income and other characteristics 
(Ochalek et al., 2015).  These two studies provide a range of estimates of health opportunity costs 
for Malawi, reflecting alternative estimation methods and assumptions.  Woods et al. (In press) 
estimate this to range between $3 and $116 per DALY averted (1% to 51% of GDP per capita) 
(Woods et al., In press); and Ochalek et al. (2015) provide estimates ranging from $24 and $37 per 
DALY averted (11% to 16% of GDP per capita) (Ochalek et al., 2015).  For the purposes of describing 
the framework, an initial estimate of $61 per DALY is employed based on the mean from these two 
papers inflated to 2016 US$.  The implications of varying this estimate for the scale of the EHP are 
assessed in Section 3.6. 
  
This starting estimate of health opportunity costs enables an assessment of what interventions are 
affordable for the EHP.  Those interventions that available evidence suggests can generate health at 
a cost that is less than the health opportunity costs are worthy of consideration.  In other words, if 
the estimated cost per DALY averted for an intervention is less than the cost at which the Malawi 
health system is able to avert DALYs (initially set at $61 per DALY averted), this is consistent with 
maximising the impact on population health given financial resource constraints.  To pay more than 
$61 per DALY averted for interventions in the EHP would be inappropriate as resources could be 
reallocated to the health system more generally and generate greater health outcomes.  Similarly, 
confining the EHP only to interventions with costs per DALY of, for example, $30 per DALY averted 
and below, would also not make sense as more could be spent on EHP interventions which improve 
population health when allowing for opportunity costs. 
 
Table 4 shows the key characteristics of the 67 candidate interventions for which evidence is 
currently available.  The interventions are ranked in terms of their incremental cost-effectiveness 
ratios (ICERs) expressed as expected cost per DALY averted.  This is also shown in terms of the 
number of DALYs averted per $1000 spend [(1/ICER) x $1000].  The table also shows, for each 
intervention; the estimated number of cases per annum, the total cost per annum, total cumulative 
cost per annum, and total DALYs averted. On the basis of an estimated health opportunity cost of 
$61 per DALY averted, the first 48 interventions in Table 4 can be afforded and, together, these 
                                                          
13
 Costs are drug and supply costs.  Further information is given in Appendix 3. 
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would cost $264.5 million per annum which can be considered an appropriate budget for the EHP.14  
The affordable interventions and implied budget are also shown in Figure 5 which plots the DALYs 
averted per $1000 against cumulative annual expenditure, again assuming 100% implementation.
                                                          
14
 We assume interventions are independent.  In reality, however, there may be complementarities between 
treatments, and the ICERs could change depending upon which other interventions are provided as part of the 
package. 
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Table 4 Prioritising interventions by effectiveness cost 
Ranking 
based on 
ICER Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum 
Total cost (Malawi 
cost * patient #s) Cumulative cost Total DALYs averted 
1 Cotrimoxazole for children cost saving 
 
127,265 $219,803 $219,803 318 
 
2 Mass media 1 903 6,879,044  $7,608,778  $7,828,581  150,390  
3 
Isoniazid Preventive Therapy for children 
in contact with TB patients 1 900 2,227  $7,321  $7,835,902  45,175  
 
4 
Isoniazid Preventive Therapy for HIV+ no 
TB 1 887 55,132  $79,518  $7,915,420  1,118,463  
5 
First line treatment for new TB cases for 
adults 3  393 14,465  $178,018  $8,093,438  1,045,196  
6 
First line treatment for retreatment TB 
cases for adults 3  393 1,808  $99,632  $8,193,071  130,651  
 
7 
First line treatment for new TB cases for 
children 3  393 12,285  $116,948  $8,310,019  887,697  
 
8 
First line treatment for retreatment TB 
cases for children 3  393 1,536  $65,831  $8,375,850  110,963  
9 
Clean practices and immediate essential 
newborn care (home) 3  368 671,464  $415,687  $8,791,536  237,281  
 
10 Case management of MDR TB cases 3  297 70  $12,249  $8,803,786  5,182  
11 
Malaria treatment: uncomplicated (adult, 
<36 kg) 4  260 4,371,692  $3,463,077  $12,266,863  59,209  
12 
Malaria treatment: uncomplicated (adult, 
>36 kg) 4  260 4,371,692  $4,267,184  $16,534,046  59,209  
13 
Malaria treatment: uncomplicated - 2nd 
line (adult, >36 kg) 4  260 4,371,692  $1,186,063  $17,720,109  59,209  
 
14 
Malaria treatment: uncomplicated - 2nd 
line (adult, <36 kg) 4  260 4,371,692  $593,031  $18,313,141  59,209  
 
15 
Malaria treatment: uncomplicated 
(children, <15 kg) 4  260 1,042,154  $4,576,454  $22,889,595  14,115  
16 
Malaria treatment: uncomplicated 
(children, >15 kg) 4  260 1,042,154  $4,768,246  $27,657,841  14,115  
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Ranking 
based on 
ICER Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum 
Total cost (Malawi 
cost * patient #s) Cumulative cost Total DALYs averted 
17 
Malaria treatment: uncomplicated - 2nd 
line (children, <15 kg) 4  260 1,042,154  $35,322  $27,693,163  14,115  
18 
Malaria treatment: uncomplicated - 2nd 
line (children, >15 kg) 4  260 1,042,154  $70,685  $27,763,848  14,115  
19 
Malaria treatment: First trimester  W 
uncomplicated 5  198 304,921  $1,025,093  $28,788,941  108,854  
20 
Malaria treatment: Second trimester  W 
uncomplicated 5  198 304,921  $235,320  $29,024,261  108,854  
21 
Malaria treatment: Pregnant women  W 
complicated 5  198 15,613  $139,592  $29,163,853  5,574  
 
22 Rotavirus vaccine 6  177 650,553  $3,096,648  $32,260,501  88,364  
23 
Management of pre-eclampsia 
(Magnesium sulphate) 6  168 20,022  $45,439  $32,305,940  534,719  
 
24 Tetanus toxoid (pregnant women) 7  149 918,437  $114,545  $32,420,485  103,602  
25 
Vitamin A supplementation in pregnant 
women 7  140 123,989  $125,197  $32,545,682  33,420  
 
26 Measles vaccine 9  106 650,553  $527,904  $33,073,586  106,659  
 
27 PMTCT 11  94 52,791  $600,432  $33,674,018  157,074  
 
28 Labour and delivery management 11  89 918,437  $1,281,436  $34,955,454  170,442  
 
29 Caesarean section (with complication) 12  86 5,051  $171,925  $35,127,380  137,341  
 
30 Management of obstructed labour 12  86 91,844  $1,099,805  $36,227,184  2,497,118  
 
31 Vaginal delivery, skilled attendance 12  83 918,437  $5,180,964  $41,408,148  66,840  
 
32 Vaginal delivery, with complication 12  83 137,766  $803,890  $42,212,038  10,026  
 
33 Households owning at least one ITN/LLIN 13  77 6,751,618  $13,736,789  $55,948,828  228,063  
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Ranking 
based on 
ICER Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum 
Total cost (Malawi 
cost * patient #s) Cumulative cost Total DALYs averted 
 
34 Pregnant women sleeping under an ITN 13  77 1,469,499  $2,989,832  $58,938,660  49,638  
 
35 
Under five children who slept under 
ITN/LLIN 13  77 494,267  $1,005,632  $59,944,292  16,696  
 
36 Antenatal care (4 visits) 15  68 918,437  $11,230,144  $71,174,436  90,020  
 
37 Blood safety 15  66 39,554  $1,625,986  $72,800,422  11,866  
 
38 Male circumcision 22  45 4,073,429  $146,729,553  $219,529,975  39,634,464  
 
39 Newborn sepsis - Full supportive care 24  42 80,576  $417,192  $219,947,167  60,156  
 
40 
Antenatal corticosteroids for preterm 
labour 25  40 165,319  $405,568  $220,352,735  47,064  
 
41 Voluntary counselling and testing 25  40 8,030,614  $36,308,732  $256,661,467  167,100  
42 Schistosomiasis mass drug administration 29  35 388,695  $76,527  $256,737,995  23,754  
 
43 Caesarean section 32  31 33,982  $671,704  $257,409,698  327,465  
 
44 Maternal sepsis case management 39  26 64,291  $2,730,718  $260,140,417  20,052  
 
45 Antibiotics for pPRoM 40  25 64,291  $38,796  $260,179,213  29,509  
 
46 
Management of severe malnutrition 
(children) 50  20 50,790  $2,436,858  $262,616,071  198,831  
 
47 
Interventions focused on female sex 
workers 51  20 23,478  $655,072  $263,271,144  161,351  
48 
Interventions focused on men who have 
sex with men 51  20 33,758  $1,255,745  $264,526,889  231,996  
 
49 High cholesterol 68  15 222,947  $6,702,709  $271,229,598  921  
 
50 
Basic psychosocial support, advice, and 
follow-up, plus anti-epileptic medication 82  12 506,371  $1,265,925  $272,495,523  689  
 
51 Zinc (diarrhoea treatment) 99  10 7,455,177  $1,787,880  $274,283,403  244,080  
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Ranking 
based on 
ICER Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum 
Total cost (Malawi 
cost * patient #s) Cumulative cost Total DALYs averted 
 
52 IPT (pregnant women) 110  9 734,750  $34,712  $274,318,115  99  
 
53 Condoms 127  8 8,030,614  $22,882,530  $297,200,645  481,837  
 
54 ORS 153  7 8,661,655  $937,089  $298,137,734  147,171  
 
55 Hypertension 159  6 845,659  $1,337,730  $299,475,465  44,495  
 
56 Treatment of depression 265  4 168,790  $331,621  $299,807,086  115  
 
57 Diabetes, Type I 296  3 23,063  $4,303,914  $304,111,000  25  
 
58 Diabetes, Type II 296  3 138,381  $4,210,622  $308,321,621  149  
 
59 ART for men 312  3 331,746  $21,159,060  $329,480,681  1,005,291  
 
60 ART for women 312  3 508,622  $32,440,372  $361,921,053  1,541,279  
 
61 Ischemic heart disease 453  2 128,130  $4,193  $361,925,246  7  
 
62 Treatment of bipolar disorder 557  2 523,250  $10,361,966  $372,287,212  182  
 
63 GIT, Intestine cancer 804  1 156  $2,711  $372,289,923  0  
 
64 Paediatric ART 892  1 106,677  $7,657,310  $379,947,233  1,556,424  
 
65 Cervical cancer (first line) 1,087  1 2,477  $161,625  $380,108,858  1  
 
66 Treatment of acute psychotic disorders 1,646  1 168,790  $958,081  $381,066,939  27  
 
67 Treatment of schizophrenia 1,646  1 2,363,066  $13,413,129  $394,480,067  376  
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Figure 5 The DALYs averted per $1,000 for EHP interventions that are affordable in Malawi given estimated 
health opportunity costs of $61 per DALY averted (or 16 DALYs averted per $1,000) 
The figure also shows cumulative spend and the implied budget for 100% implementation of each intervention 
to its relevant target population.  The number shown for each intervention relate to the ICER ranking in Table 
4. 
 
3.3 Maximising gains in population health from the available budget 
Although ICERs are an appropriate way of establishing which interventions are affordable for the EHP 
given what Malawi currently spends to generate health (here taken as $61 per DALY averted), they 
cannot be used to prioritise between interventions on the basis of overall gains in population health 
(i.e. to establish which interventions maximise population health subject to the available budget).  This 
is because prioritising on the basis of ICERs does not consider the size of an intervention's health gain 
per patient or the number of patients who stand to benefit from the intervention net of the health 
opportunity cost of the intervention.   Table 5 shows the ranking of interventions in terms of overall 
gains in population health expressed as net DALYs averted assuming 100% intervention 
implementation for each target population.  Net DALYs averted are calculated as follows: 
 ܦ௜ െ ܥ௜݇ 
 
Where: 
x ܦ௜ is the DALYs averted across the relevant population for each intervention ݅ (Column 8 in Table 
5). 
x ܥ௜ is the total annual cost across the relevant population of each intervention ݅ (Column 6 in Table 
5)15. 
x ݇ is the health opportunity cost (the cost of averting an additional DALY elsewhere in the health 
system). 
                                                          
15
 Net DALYs averted are calculated using the same cost as are used to calculate the cost-effectiveness ratios.  These are not 
always equal to the Malawi per patient costs which are presented in column 6 and are used to calculate the size of the 
package.  This is discussed further in Appendix 3. 
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Several things can be noted from Table 5.  Firstly, as expected, the ranking based on net DALYs averted 
is rather different to that based on ICERs.  For example, male circumcision is ranked first compared to 
its ICER ranking of thirty-eighth, which reflects the fact that it generates a large health impact on its 
target population which remains higher than other interventions even when health opportunity costs 
are considered.  The second thing to note is that the cost saving intervention ranked first by ICER (i.e. 
intervention 1) averts fewer net DALYs overall than other interventions which impose costs on the 
system.  This is because the direct health effects of the cost saving intervention plus the opportunity 
gains (health produced elsewhere from the savings generated by the intervention) are less than those 
of cost-adding interventions.  The third consideration is that those interventions that cannot be 
afforded by the EHP and were not included in the package in Table 4 and Figure 5 would result in 
negative overall population health impacts (net DALYs averted) if they had been included.  This is 
because the cost associated with those interventions could be used elsewhere to better effect (i.e. the 
resources would generate higher DALYs averted than if used for these particular interventions).  Figure 
6 shows the re-ranking based on net gains in population health, where the latter is compared with 
cumulative spend.  Those interventions that cannot be afforded (beyond the budget of $264.5 million 
with ICERs above $61 per DALY averted) are shown to generate negative net DALYs averted.
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Table 5 Prioritising interventions in terms of impact on overall population health (net DALYs averted) 
# Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum Total cost Cumulative cost 
Total DALYs 
averted 
Net DALYs 
averted (full 
implementation) 
 
38 Male circumcision 22  45  4,073,429  $146,729,553  $146,729,553  39,634,464  25,423,008  
 
30 Management of obstructed labour 12  86  91,844  $1,099,805  $147,829,358  2,497,118  2,025,734  
4 
Isoniazid Preventive Therapy for HIV+ no 
TB 1  887  55,132  $79,518  $147,908,876  1,118,463  1,097,909  
5 
First line treatment for new TB cases for 
adults 3  393  14,465  $178,018  $148,086,894  1,045,196  1,001,800  
7 
First line treatment for new TB cases for 
children 3  393  12,285  $116,948  $148,203,842  887,697  850,840  
23 
Management of pre-eclampsia 
(Magnesium sulphate) 6  168  20,022  $45,439  $148,249,281  534,719  482,789  
9 
Clean practices and immediate essential 
newborn care (home) 3  368  671,464  $415,687  $148,664,968  237,281  226,760  
 
33 Households owning at least one ITN/LLIN 13  77  6,751,618  $13,736,789  $162,401,757  228,063  179,981  
 
43 Caesarean section 32  31  33,982  $671,704  $163,073,461  327,465  156,536  
 
2 Mass media 1  903  16,879,044  $7,608,778  $170,682,239  150,390  147,674  
 
28 Labour and delivery management 11  89  918,437  $1,281,436  $171,963,675  170,442  139,385  
 
27 PMTCT 11  94  52,791  $600,432  $172,564,107  157,074  129,751  
 
6 
First line treatment for retreatment TB 
Cases for adults 3  393  1,808  $99,632  $172,663,740  130,651  125,227  
 
29 Caesarean section (with complication) 12  86  5,051  $171,925  $172,835,665  137,341  111,415  
8 
First line treatment for retreatment TB 
Cases for children 3  393  1,536  $65,831  $172,901,496  110,963  106,356  
19 
Malaria treatment: First trimester  W 
uncomplicated 5  198  304,921  $1,025,093  $173,926,589  108,854  99,904  
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# Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum Total cost Cumulative cost 
Total DALYs 
averted 
Net DALYs 
averted (full 
implementation) 
20 
Malaria treatment: Second trimester  W 
uncomplicated 5  198  304,921  $235,320  $174,161,909  108,854  99,904  
 
41 Voluntary counselling and testing 25  40  8,030,614  $36,308,732  $210,470,641  167,100  98,199  
 
24 Tetanus toxoid (pregnant women) 7  149  918,437  $114,545  $210,585,186  103,602  92,231  
 
26 Measles vaccine 9  106  650,553  $527,904  $211,113,090  106,659  90,230  
 
22 Rotavirus vaccine 6  177  650,553  $3,096,648  $214,209,738  88,364  80,205  
 
36 Antenatal care (4 visits) 15  68  918,437  $11,230,144  $225,439,882  90,020  68,482  
 
11 
Malaria treatment: uncomplicated (adult, 
<36 kg) 4  260  4,371,692  $3,463,077  $228,902,959  59,209  55,503  
 
12 
Malaria treatment: uncomplicated (adult, 
>36 kg) 4  260  4,371,692  $4,267,184  $233,170,142  59,209  55,503  
 
13 
Malaria treatment: uncomplicated - 2nd 
line (adult, >36 kg) 4  260  4,371,692  $1,186,063  $234,356,205  59,209  55,503  
 
14 
Malaria treatment: uncomplicated - 2nd 
line (adult, <36 kg) 4  260  4,371,692  $593,031  $234,949,236  59,209  55,503  
 
31 Vaginal delivery, skilled attendance 12  83  918,437  $5,180,964  $240,130,200  66,840  53,706  
 
3 
Isoniazid Preventive Therapy for children 
in contact with TB patients 1  900  2,227  $7,321  $240,137,521  45,175  44,357  
 
48 
Interventions focused on men who have 
sex with men 51  20  33,758  $1,255,745  $241,393,266  231,996  39,656  
 
34 Pregnant women sleeping under an ITN 13  77  1,469,499  $2,989,832  $244,383,098  49,638  39,173  
 
39 Newborn sepsis - full supportive care 24  42  80,576  $417,192  $244,800,290  60,156  36,567  
46 
Management of severe malnutrition 
(children) 50  20  50,790  $2,436,858  $247,237,148  198,831  36,343  
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# Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum Total cost Cumulative cost 
Total DALYs 
averted 
Net DALYs 
averted (full 
implementation) 
25 
Vitamin A supplementation in pregnant 
women 7  140  123,989  $125,197  $247,362,345  33,420  29,517  
40 
Antenatal corticosteroids for preterm 
labour 25  40  165,319  $405,568  $247,767,913  47,064  28,004  
47 
Interventions focused on female sex 
workers 51  20  23,478  $655,072  $248,422,986  161,351  27,581  
 
1 Cotrimoxazole for children -4,289  0 127,265  $219,803  $248,642,789  318  22,564  
15 
Malaria treatment: uncomplicated 
(children, <15 kg) 4  260  1,042,154  $4,576,454  $253,219,243  14,115  13,231  
16 
Malaria treatment: uncomplicated 
(children, >15 kg) 4  260  1,042,154  $4,768,246  $257,987,489  14,115  13,231  
17 
Malaria treatment: uncomplicated - 2nd 
line (children, <15 kg) 4  260  1,042,154  $35,322  $258,022,811  14,115  13,231  
18 
Malaria treatment: uncomplicated - 2nd 
line (children, >15 kg) 4  260  1,042,154  $70,685  $258,093,496  14,115  13,231  
35 
Under five children who slept under 
ITN/LLIN 13  77  494,267  $1,005,632  $259,099,129  16,696  13,176  
42 Schistosomiasis mass drug administration 29   35  388,695  $76,527  $259,175,656  23,754  12,562  
 
45 Antibiotics for pPRoM 40  25  64,291  $38,796  $259,214,452  29,509  10,473  
 
37 Blood safety 15   66  39,554  $1,625,986  $260,840,439  11,866  8,914  
 
32 Vaginal delivery, with complication 12  83  137,766  $803,890  $261,644,329  10,026  8,056  
 
44 Maternal sepsis case management 39  26  64,291  $2,730,718  $264,375,047  20,052  7,324  
 
21 
Malaria treatment: pregnant women  W 
complicated 5  198  15,613  $139,592  $264,514,639  5,574  5,116  
 
10 Case management of MDR TB cases 3  297  70  $12,249  $264,526,889  5,182  4,898  
 
63 GIT, Intestine cancer 804  1  156  $2,711  $264,529,599  0  -0  
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# Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum Total cost Cumulative cost 
Total DALYs 
averted 
Net DALYs 
averted (full 
implementation) 
 
65 Cervical cancer (first line) 1,087  1  2,477  $161,625  $264,691,224  1  -15  
 
61 Ischemic heart disease 453  2  128,130  $4,193  $264,695,417  7  -45  
 
52 IPT (pregnant women) 110  9  734,750  $34,712  $264,730,129  99  -79  
 
57 Diabetes, Type I 296  3  23,063  $4,303,914  $269,034,043  25  -95  
 
49 High cholesterol 68  15  222,947  $6,702,709  $275,736,752  921  -98  
50 
Basic psychosocial support, advice, and 
follow-up, plus anti-epileptic medication 82  12  506,371  $1,265,925  $277,002,677  689  -237  
 
56 Treatment of depression 265  4  168,790  $331,621  $277,334,298  115  -382  
 
58 Diabetes, Type II 296  3  138,381  $4,210,622  $281,544,920  149  -568  
 
66 Treatment of acute psychotic disorders 1,646  1  168,790  $958,081  $282,503,000  27  -693  
 
62 Treatment of bipolar disorder 557  2  523,250  $10,361,966  $292,864,966  182  -1,466  
 
67 Treatment of schizophrenia 1,646  1  2,363,066  $13,413,129  $306,278,095  376  -9,704  
 
55 Hypertension 159  6  845,659  $1,337,730  $307,615,825  44,495  -70,870  
 
51 Zinc (diarrhoea treatment) 99  10  7,455,177  $1,787,880  $309,403,705  244,080  -150,097  
 
54 ORS 153  7  8,661,655  $937,089  $310,340,795  147,171  -220,736  
 
53 Condoms 127  8  8,030,614  $22,882,530  $333,223,325  481,837  -517,166  
         
 
59 ART for men 312  3  331,746  $21,159,060  $354,382,385  1,005,291  -4,103,927  
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# Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum Total cost Cumulative cost 
Total DALYs 
averted 
Net DALYs 
averted (full 
implementation) 
 
60 ART for women 312  3  508,622  $32,440,372  $386,822,757  1,541,279  -6,292,006  
 
64 Paediatric ART 892  1  106,677  $7,657,310  $394,480,067  1,556,424  -21,073,939  
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Figure 6 Interventions ranked by net DALYs averted, also showing cumulative spend (assuming 100% 
implementation) 
Shows negative net DALYs averted associated with interventions that cannot be afforded in the package. 
 
3.4 Maximising gains in population health from the available budget 
3.4.1 Health effects of less than 100% implementation 
So far it has been assumed that each intervention included in the EHP on the basis of affordability is 
delivered to 100% of its target population.  The reality is, however, implementation rarely, if ever, 
reaches this level.  As discussed in Sections 1 and 2 with examples, this reflects a range of possible 
constraints that operate in health systems, which can be particularly acute in low-income settings.  
Some of these relate to the demand side  W patients failing to take up or to adhere to interventions W 
and some to the supply side  W challenges in getting services to patients.  Some of these constraints 
are specific to particular interventions, and others apply across interventions and relate to the 
ŚĞĂůƚŚĐĂƌĞƐǇƐƚĞŵ ?ƐǁĞĂŬŶĞƐƐes more generally. 
 
The analytical framework that has been developed provides a means of quantifying the impact on 
population health of this range of intervention-specific and system-level constraints.  This is shown 
diagrammatically in Figure 7 which looks at those interventions included in the EHP (based on Tables 
4 and 5) at a budget of $264.5 million.  As before, the figure shows the overall impact on population 
health (net of health opportunity costs) in terms of net DALYs averted, and the cumulative spend 
across the package.  The solid lines show what happens to these metrics when interventions achieve 
100% implementation.  The dotted lines indicate how net DALYs averted decline as implementation 
levels fall; the dotted line also shows the underspend on the EHP budget as fewer patients from the 
target populations receive the relevant interventions. 
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Figure 7 Interventions ranked by net DALYs averted, also showing cumulative spend 
Compares full (100% implementation) [solid lines] with lower (<100% implementation) [dotted lines].  
Shows impact of limited implementation on net DALYs averted and the budget underspend. 
 
More detail is provided in Table 6 that shows the key metrics with full and partial implementation  W 
spending levels on the intervention (and cumulatively across interventions), DALYs averted and net 
DALYs averted.  The partial levels of implementation are based on what is considered realistic in the 
Malawi setting and are from a bottleneck analysis from the EHP HSSPII midterm costing (v87).  The 
ƚĂďůĞĂůƐŽƐŚŽǁƐƚŚĞŝŵƉĂĐƚŽĨƚŚĞ ?ŝŵƉůĞŵĞŶƚĂƚŝŽŶŐĂƉ ?ŽŶŶĞƚ>zƐĂǀĞƌƚĞĚ ?&ŽƌĞǆĂŵƉůĞ ?Ă
realistic implementation level for first line treatment of TB in children is 64%.  This will generate 
850,840 net DALYs averted under full implementation, but only 544,538 at the lower level of 
implementation, resulting in a net loss to overall population health of 306,303 DALYs averted.  The 
table also shows the magnitude of the budget underspend associated with partial implementation, 
both at an intervention level and cumulatively across the package.  Overall the cumulative cost 
under partial implementation is $66.7 million from a budget of $264.5 million (underspend of $197.9 
million).  The information in Table 6 provides useful insights for policy makers considering how to 
respond to partial implementation of EHP interventions.  The framework provides a coherent means 
of bringing together resource allocation decisions relating to specific interventions funded through 
the EHP and those relating to implementation and system strengthening. 
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Table 6 Impact on overall population health (net DALYs averted) and cumulative spend of interventions included in the EHP with 100% implementation and expected (realistic) levels of 
implementation 
# Intervention 
ICER 
[$] 
Pop 
DALYs 
averted 
per 
1,000 
Cases per 
annum 
Implem ?
level 
Total cost 
(full 
implem ?) 
[$] 
Cumulative 
cost (full 
implem·) [$] 
Total cost 
(realistic 
implem·) [$] 
Cumulative 
cost 
(realistic 
implem·) [$] 
Total 
DALYs 
averted (full 
implem·) 
Total 
DALYs 
averted 
(realistic 
implem·) 
Net DALYs 
averted (full 
implem·) 
Net DALYs 
averted 
(realistic 
implem·) 
Difference 
in net 
DALYs 
averted 
$ value to the 
health care 
system of 
implem ? 
38 Male circumcision 22 45  4,073,429  12% 
 
146,729,553  146,729,553  17,607,546  17,607,546   39,634,464  4,756,136   25,423,008  3,050,761   22,372,247   1,372,313,607  
4 
Isoniazid Preventive 
Therapy for HIV+ no 
TB 1 887  55,132  50%  79,518  146,809,071  39,759  17,647,305   1,118,463  559,231  1,097,909  548,955   548,955   33,672,879  
5 
First line treatment 
for new TB Cases 
for adults 3 393  14,465  64%  178,018  146,987,089  113,932  17,761,237   1,045,196  668,925  1,001,800  641,152   360,648   22,122,152  
7 
First line treatment 
for new TB Cases 
for children 3 393  12,285  64%  116,948  147,104,037  74,847  17,836,084   887,697  568,126  850,840  544,538   306,303   18,788,597  
9 
Clean practices and 
immediate essential 
newborn care 
(home) 3 368  671,464  0%  415,687  147,519,724  0    17,836,084   237,281  0    226,760  0     226,760   13,909,438  
23 
Management of 
pre-eclampsia 
(Magnesium 
sulphate) 6 168  20,022  80%  45,439  147,565,163  36,351  17,872,435   534,719  427,775  482,789  386,231   96,558   5,922,852  
41 
Voluntary 
counselling and 
testing 25 40  8,030,614  15%  36,308,732  183,873,895  5,446,310  23,318,745   167,100  25,065  98,199  14,730   83,469   5,119,998  
 
22 Rotavirus vaccine 6 177  650,553  0%  3,096,648  186,970,543  0    23,318,745   88,364  0    80,205  0     80,205   4,919,790  
33 
Households owning 
at least one 
ITN/LLIN 13 77  6,751,618  56%  13,736,789  200,707,333  7,706,339  31,025,084   228,063  127,944  179,981  100,969   79,012   4,846,582  
19 
Malaria treatment: 
First trimester - 
uncomplicated 5 198  304,921  33%  1,025,093  201,732,426  341,356  31,366,440   108,854  36,248  99,904  33,268   66,636   4,087,451  
 
27 PMTCT 11 94  52,791  55%  600,432  202,332,858  331,814  31,698,253   157,074  86,803  129,751  71,704   58,047   3,560,625  
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# Intervention 
ICER 
[$] 
Pop 
DALYs 
averted 
per 
1,000 
Cases per 
annum 
Implem ?
level 
Total cost 
(full 
implem ?) 
[$] 
Cumulative 
cost (full 
implem·) [$] 
Total cost 
(realistic 
implem·) [$] 
Cumulative 
cost 
(realistic 
implem·) [$] 
Total 
DALYs 
averted (full 
implem·) 
Total 
DALYs 
averted 
(realistic 
implem·) 
Net DALYs 
averted (full 
implem·) 
Net DALYs 
averted 
(realistic 
implem·) 
Difference 
in net 
DALYs 
averted 
$ value to the 
health care 
system of 
implem ? 
13 
Malaria treatment: 
uncomplicated - 
2nd line (adult, >36 
kg) 4 260  4,371,692  2% 1,186,063  203,518,921  17,791  31,716,044   59,209  888  55,503  833   54,671   3,353,500  
14 
Malaria treatment: 
uncomplicated - 
2nd line (adult, <36 
kg) 4 260  4,371,692  4% 593,031  204,111,952  20,756  31,736,800   59,209  2,072  55,503  1,943   53,561   3,285,409  
28 
Labour and delivery 
management 11 89  918,437  65% 1,281,436  205,393,388  832,934  32,569,734   170,442  110,787  139,385  90,601   48,785   2,992,465  
6 
First line treatment 
for retreatment TB 
cases for adults 3 393  1,808  65% 99,632  205,493,021  64,761  32,634,495   130,651  84,923  125,227  81,397   43,829   2,688,491  
 
2 Mass media 1 903  16,879,044  71% 7,608,778  213,101,799  5,402,232  38,036,727   150,390  106,777  147,674  104,849   42,826   2,626,920  
11 
Malaria treatment: 
uncomplicated 
(adult, <36 kg) 4 260  4,371,692  30% 3,463,077  216,564,876  1,038,923  39,075,651   59,209  17,763  55,503  16,651   38,852   2,383,198  
48 
Interventions 
focused on men 
who have sex with 
men 51 20  33,758  5% 1,255,745  217,820,621  62,787  39,138,438   231,996  11,600  39,656  1,983   37,673   2,310,888  
36 
Antenatal care (4 
visits) 15 68  918,437  46% 11,230,144  229,050,765  5,109,715  44,248,153   90,020  40,959  68,482  31,159   37,323   2,289,380  
8 
First line treatment 
for retreatment TB 
cases for children 3 393  1,536  65% 65,831  229,116,596  42,790  44,290,944   110,963  72,126  106,356  69,131   37,224   2,283,350  
20 
Malaria treatment: 
Second trimester - 
uncomplicated 5 198  304,921  67% 235,320  229,351,915  156,723  44,447,666   108,854  72,497  99,904  66,536   33,368   2,046,790  
40 
Antenatal 
corticosteroids for 
preterm labour 25 40  165,319  0% 405,568  229,757,483  0    44,447,666   47,064  0    28,004  0     28,004   1,717,752  
39 
Newborn sepsis - 
Full supportive care 24 42  80,576  40% 417,192  230,174,675  166,877  44,614,543   60,156  24,062  36,567  14,627   21,940   1,345,802  
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# Intervention 
ICER 
[$] 
Pop 
DALYs 
averted 
per 
1,000 
Cases per 
annum 
Implem ?
level 
Total cost 
(full 
implem ?) 
[$] 
Cumulative 
cost (full 
implem·) [$] 
Total cost 
(realistic 
implem·) [$] 
Cumulative 
cost 
(realistic 
implem·) [$] 
Total 
DALYs 
averted (full 
implem·) 
Total 
DALYs 
averted 
(realistic 
implem·) 
Net DALYs 
averted (full 
implem·) 
Net DALYs 
averted 
(realistic 
implem·) 
Difference 
in net 
DALYs 
averted 
$ value to the 
health care 
system of 
implem ? 
1 
Cotrimoxazole for 
children 
cost 
saving 
 
127,265  13% 219,803  230,394,478  27,927  44,642,470   318  40  22,564  2,867   19,698   1,208,247  
47 
Interventions 
focused on female 
sex workers 51 20  23,478  30% 655,072  231,049,551  196,522  44,838,992   161,351  48,405  27,581  8,274   19,306   1,184,254  
31 
Vaginal delivery, 
skilled attendance 12 83  918,437  65% 5,180,964  236,230,515  3,367,627  48,206,618   66,840  43,446  53,706  34,909   18,797   1,153,016  
12 
Malaria treatment: 
uncomplicated 
(adult, >36 kg) 4 260  4,371,692  70% 4,267,184  240,497,698  2,987,028  51,193,647   59,209  41,446  55,503  38,852   16,651   1,021,371  
24 
Tetanus toxoid 
(pregnant women) 7 149  918,437  84% 114,545  240,612,243  96,218  51,289,864   103,602  87,025  92,231  77,474   14,757   905,196  
17 
Malaria treatment: 
uncomplicated - 
2nd line (children, 
<15 kg) 4 260  1,042,154  2% 35,322  240,647,565  530  51,290,394   14,115  212  13,231  198   13,033   799,431  
18 
Malaria treatment: 
uncomplicated - 
2nd line (children, 
>15 kg) 4 260  1,042,154  4% 70,685  240,718,250  2,474  51,292,868   14,115  494  13,231  463   12,768   783,199  
42 
Schistosomiasis 
mass drug 
administration 29 35  388,695  13% 76,527  240,794,777  9,949  51,302,817   23,754  3,088  12,562  1,633   10,929   670,393  
25 
Vitamin A 
supplementation in 
pregnant women 7 140  123,989  65% 125,197  240,919,974  81,378  51,384,195   33,420  21,723  29,517  19,186   10,331   633,694  
16 
Malaria treatment: 
uncomplicated 
(children, >15 kg) 4 260  1,042,154  40% 4,768,246  245,688,221  1,907,299  53,291,494   14,115  5,646  13,231  5,292   7,939   486,963  
45 
Antibiotics for 
pPRoM 40 25  64,291  30% 38,796  245,727,017  11,639  53,303,132   29,509  8,853  10,473  3,142   7,331   449,676  
44 
Maternal sepsis 
case management 39 26  64,291  0% 2,730,718  248,457,735  0    53,303,132   20,052  0    7,324  0     7,324   449,255  
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# Intervention 
ICER 
[$] 
Pop 
DALYs 
averted 
per 
1,000 
Cases per 
annum 
Implem ?
level 
Total cost 
(full 
implem ?) 
[$] 
Cumulative 
cost (full 
implem·) [$] 
Total cost 
(realistic 
implem·) [$] 
Cumulative 
cost 
(realistic 
implem·) [$] 
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implem·) 
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DALYs 
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averted (full 
implem·) 
Net DALYs 
averted 
(realistic 
implem·) 
Difference 
in net 
DALYs 
averted 
$ value to the 
health care 
system of 
implem ? 
46 
Management of 
severe malnutrition 
(children) 50 20  50,790  80% 2,436,858  250,894,594  1,949,487  55,252,619   198,831  159,065  36,343  29,074   7,269   445,853  
3 
Isoniazid Preventive 
Therapy for 
children in contact 
with TB patients 1 900  2,227  85% 7,321  250,901,915  6,223  55,258,842   45,175  38,398  44,357  37,703   6,654   408,127  
15 
Malaria treatment: 
uncomplicated 
(children, <15 kg) 4 260  1,042,154  60% 4,576,454  255,478,369  2,745,873  58,004,714   14,115  8,469  13,231  7,939   5,292   324,642  
32 
Vaginal delivery, 
with complication 12 83  137,766  51% 803,890  256,282,259  409,984  58,414,698   10,026  5,113  8,056  4,109   3,947   242,133  
 
26 Measles vaccine 9 106  650,553  99% 527,904  256,810,163  522,625  58,937,323   106,659  105,593  90,230  89,328   902   55,347  
30 
Management of 
obstructed labour 12 86  91,844  100% 1,099,805  257,909,968  1,099,805  60,037,128   2,497,118  2,497,118  2,025,734  2,025,734  0 0 
 
43 Caesarean section 32 31  33,982  100% 671,704  258,581,671  671,704  60,708,831   327,465  327,465  156,536  156,536  0    0 
29 
Caesarean section 
(with complication) 12 86  5,051  100% 171,925  258,753,597  171,925  60,880,757   137,341  137,341  111,415  111,415  0    0 
34 
Pregnant women 
sleeping under an 
ITN 13 77  1,469,499  100% 2,989,832  261,743,428  2,989,832  63,870,589   49,638  49,638  39,173  39,173  0    0 
35 
Under five children 
who slept under 
ITN/LLIN 13 77  494,267  100% 1,005,632  262,749,061  1,005,632  64,876,221   16,696  16,696  13,176  13,176  0    0 
 
37 Blood safety 15 66  39,554  100% 1,625,986  264,375,047  1,625,986  66,502,207   11,866  11,866  8,914  8,914  0    0 
21 
Malaria treatment: 
pregnant women - 
complicated 5 198  15,613  100% 139,592  264,514,639  139,592  66,641,799   5,574  5,574  5,116  5,116  0    0 
10 
Case management 
of MDR TB cases 3 297  70  100% 12,249  264,526,889  12,249  66,654,049   5,182  5,182  4,898  4,898  0    0 
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3.4.2 Prioritising intervention-specific implementation activities 
A range of policy options exist to address the constraints facing specific interventions that result in 
implementation below 100%.  These could relate to the demand side (e.g. initiatives to address 
ƉĂƚŝĞŶƚƐ ?ůĂĐŬŽĨƵƉƚĂŬĞŽƌĂĚŚĞƌĞŶĐĞƚŽĂŐŝǀĞŶintervention) or supply side (e.g. investment in staff 
training to ensure an intervention is delivered appropriately).  Policy makers are unlikely to be able 
to initiate implementation-enhancing activities for all interventions with partial implementation, and 
prioritisation will be necessary.  Prioritisation of such activities by intervention is informed by the 
magnitude of loss in population health net of health opportunity cost (net DALYs averted) shown in 
Table 6.  Those interventions with the biggest losses in net DALYs averted as a result of their 
implementation gaps are the ones with the greatest potential benefits from implementation 
activities because such activities have scope to remove the losses.  It is important to emphasise 
 ?potential ?, as the implementation activity would have to remove the implementation gap entirely to 
achieve these gains in overall health.  Nonetheless, although best evidence on the effectiveness and 
cost of the implementation activity would need to be considered (in order to estimate actual gains in 
overall population health), this provides an initial indication of where a policy to enhance 
implementation might be prioritised.  
 
Table 6 also shows how much the Malawian health care system might devote to intervention-
specific implementation activities; it shows the maximum value, in monetary terms, of policies that 
remove the implementation gap for each intervention.  In other words, this is the maximum the 
health system should spend on those activities given health opportunity cost (i.e. given the DALYs 
averted that could be achieved from other activities in the system).  It is important to emphasise 
that these values relate to the whole health system and may not be affordable solely from the EHP 
budget of $264.5 million.    
 
This is illustrated further in Figure 8 which shows the overall health impact (additional net DALYs 
averted) associated with eliminating the implementation gap (i.e. taking implementation to 100%) 
with different levels of expenditure on intervention-specific implementation activities.  Each 
function relates to a specific intervention as would be realistically implemented at the rates shown 
in Table 6 (i.e. less than 100%).  Where a function cuts the horizontal axis, this shows a level of 
expenditure to remove the implementation gap that is equal to the maximum monetary value to the 
health care system of implementation.  If the system were to devote this amount to 
implementation-enhancing activities it would not generate any overall health gain (precisely zero 
additional net DALYs averted on the vertical axis) because this is the maximum value the system can 
afford.  Any more expenditure than this would result in negative net DALYs averted, as shown with 
the function moving below the horizontal axis with higher levels of implementation expenditure.  
The net DALYs averted with zero expenditure shows how much overall health can be achieved (gains 
in net DALYs averted) from removing the implementation gap when the implementation activities 
cost nothing.  This might be the case, for example, if these activities are funded from outside the 
health care system.  This is the same as the maximum overall health benefit that can be achieved 
from implementation, equivalent to the loss in net DALYs averted shown in Table 6.  The slope of 
each line is the same in the figure, reflecting the rate at which the health system is able to transform 
financial resources into DALYs averted (assumed $61 per DALY averted here).  All that varies 
between the interventions, therefore, is the maximum value of implementation activities in health 
terms or monetary terms. 
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Figure 8 Net DALYs averted at different investment levels for intervention-specific implementation activities 
for those interventions in the EHP 
 
3.4.3 System-level constraints and system strengthening 
Some constraints may relate to specific interventions, but others may impact on the implementation 
of several or all interventions.  There may be scope for system strengthening policies that impact on 
these system-level constraints.  Such policies might include, on the demand side, providing better 
transport facilities to get patients to health care facilities; on the supply side they may include 
providing more secure electricity and water supplies.  The framework provides an indication of the 
maximum potential value of system strengthening and can support decisions regarding whether 
such policies should be prioritised over intervention-specific activities.  Given an existing budget for 
the EHP of $264.5 million, the maximum potential value in health terms of system strengthening 
would be the additional DALYs averted by removing the implementation gap across all interventions 
 W i.e. the aggregate of additional DALYs averted across interventions.  Aggregating the total DALYs 
averted at 100% implementation across the interventions in the package in Table 6 (49.5 million) 
and subtracting the total DALYs averted under expected (realistic) levels of implementation (11.4 
million) gives the loss in averted QALYs from partial implementation.  This is equivalent to the 
maximum that system strengthening could achieve in health terms if it removed the implementation 
gaps for all interventions (38.0 million DALYs averted).    
 
This maximum potential gain from system strengthening can be considered alongside the 
underspend on the budget due to partial implementation discussed above ($197.9 million), which 
could be used for implementation activities and system strengthening.   In principle, the entire 
underspend could be used on system strengthening activities.  However, as this would exhaust the 
EHP budget, there would be nothing remaining to spend on actually delivering the existing 
interventions to additional in-need patients.  In other words, although longer-term health benefits 
may be realised from a stronger health system, there would be no immediate health gain (additional 
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DALYs averted) if the entire EHP underspend was devoted to system strengthening because this 
would not impact on direct patient care.   However, if system strengthening was funded partly or 
wholly from outside of the health care sector (e.g. by donors and/or central government), then all or 
part of the underspend on the EHP budget could be devoted to direct funding of existing 
interventions for which additional implementation is made feasible by the system strengthening.   
  
This is illustrated in Figure 9 which plots DALYs averted against total expenditure on the EHP with a 
budget of $264.5 million.  Two points are plotted.  Point A shows the DALYs averted when the 
system strengthening activities are funded from outside the Malawian health system.  This allows 
the entire underspend to be devoted to delivering the interventions within the stronger system.  
Assuming system strengthening is able to remove the implementation gap entirely for all 
interventions, the EHP can achieve DALYs averted from full implementation (49.5 million).  Point B 
shows the point where the entire underspend in the EHP due to partial implementation is devoted 
to system strengthening.  This means that no funding remains to deliver the interventions to 
additional patients.  This results in the aggregate DALYs averted from existing partial levels of 
implementation (11.4 million).   Of course some mix of these two positions is possible: some of the 
underspend is used to fund system strengthening and the remainder is available to pay for increased 
delivery of the existing interventions to some level above what is estimated to be realistic levels of 
implementation, exploiting the stronger system.  This would achieve a higher level of DALYs averted 
than Point B, but lower than Point A.  Where it is possible for the EHP to locate between these points 
will depend on (i) the amount of funding for system strengthening that is available from outside of 
the health care system; and (ii) the extent to which system strengthening allows the system to 
increase the implementation of specific interventions. 
 
 
Figure 9 The value of health system strengthening in terms of DALYs averted depending on what proportion 
of the underspend in the total EHP budget of $264.5 million is devoted to system strengthening versus 
intervention delivery 
Shows two points: A where system strengthening is funded from entirely outside the health system, and B 
where the underspend is devoted entirely to system strengthening. 
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3.4.4 Accepting realistic levels of implementation and funding additional interventions 
Rather than using the underspend on the EHP budget due to partial implementation of existing 
interventions on implementation activities and system strengthening, it could be devoted to 
extending the package.  That is, to accept the intervention- and system-level constraints and the 
resulting partial implementation of interventions, and to use the budget underspend to fund the 
inclusion of additional interventions that were initially excluded as they had cost per DALY averted 
estimates greater than $61.  This is shown in Table 7 which indicates that the budget underspend 
($197.9 million) could be used to include interventions 49 to 67 (see Table 4), in each case 
implemented at realistic levels (potentially less than 100%).  This would generate 14.2 million DALYs 
averted across the whole expanded package, up to an additional 2.7 million compared to the original 
package of partially implemented interventions.  It should be noted, however, that expanding the 
package may impact on the implementation levels of currently provided interventions, and as such, 
this is likely an overestimate of the true number of DALYs that would be generated. 
 
This is further illustrated in Figure 10 which shows a new point, C, added to the chart in Figure 9.  
This point corresponds to devoting the entire EHP budget underspend to expanding the package.  It 
contrasts with Point A, where system strengthening is externally funded and removes the entire 
implementation gap across all interventions, allowing the budget underspend to be used to fund the 
initial set of interventions up to 100%.  Point C also contrasts with Point B where the budget 
underspend is devoted to system strengthening alone, leaving no budget for taking implementation 
above the initial levels.  These three points represent distinct policy approaches to under-
implementation due to intervention- and system-level constraints.  In reality, a mix of these 
approaches is likely.  For example, there may be a point on Figure 10 that represents the use of the 
underspend on a mix of system strengthening and delivering existing interventions to more patients 
made possible by a stronger system.  If that point lies between points C and B, policy makers are 
likely to be influenced by the fact that it will be delivering fewer DALYs averted than using the 
underspend to add new interventions to an expanded package,  accepting lower implementation 
and not seeking to address the constraints in the system.  It should be noted that it may be the case 
that using the entire underspend on funding system strengthening would result in no immediate 
health improvement but there are likely to be longer term effects on the ability of the system to 
generate greater population health through a stronger health care system. 
 
Figure 10 The value of health system strengthening in terms of DALYs averted depending on what 
proportion of the underspend in the total EHP budget of $197.9 million is devoted to system strengthening 
versus intervention delivery 
The addition of a third point C to those shown in Figure 9 indicates the effects of using the budget 
underspend on expanding the package.
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Table 7 DALYs averted and cumulative costs of additional interventions to the package to allocate the EHP budget underspend due to partial implementation 
# Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum 
Implementation 
level 
Total cost (realistic 
implementation) 
Cumulative cost 
(realistic 
implementation) 
Total DALYs 
averted (realistic 
implementation) 
 
1 Cotrimoxazole for children 
cost 
saving   127,265  13% $27,927  $27,927  40  
 
2 Mass media 1  903  16,879,044  71% $5,402,232  $5,430,159  106,777  
3 
Isoniazid Preventive Therapy for 
children in contact with TB patients 1  900  2,227  85% $6,223  $5,436,382  38,398  
4 
Isoniazid Preventive Therapy for HIV+ 
no TB 1  887  55,132  50% $39,759  $5,476,141  559,231  
5 
First line treatment for new TB cases for 
adults 3  393  14,465  64% $113,932  $5,590,073  668,925  
6 
First line treatment for retreatment TB 
cases for adults 3  393  1,808  65% $64,761  $5,654,834  84,923  
7 
First line treatment for new TB cases for 
children 3  393  12,285  64% $74,847  $5,729,681  568,126  
8 
First line treatment for retreatment TB 
cases for children 3  393  1,536  65% $42,790  $5,772,471  72,126  
9 
Clean practices and immediate essential 
newborn care (home) 3  368  671,464  0% $0    $5,772,471  0    
 
10 Case management of MDR TB cases 3  297  70  100% $12,249  $5,784,720  5,182  
11 
Malaria treatment: uncomplicated 
(adult, <36 kg) 4  260  4,371,692  30% $1,038,923  $6,823,643  17,763  
12 
Malaria treatment: uncomplicated 
(adult, >36 kg) 4  260  4,371,692  70% $2,987,028  $9,810,672  41,446  
13 
Malaria treatment: uncomplicated - 2nd 
line (adult, >36 kg) 4  260  4,371,692  2% $17,791  $9,828,463  888  
14 
Malaria treatment: uncomplicated - 2nd 
line (adult, <36 kg) 4  260  4,371,692  4% $20,756  $9,849,219  2,072  
15 
Malaria treatment: uncomplicated 
(children, <15 kg) 4  260  1,042,154  60% $2,745,873  $12,595,091  8,469  
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# Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum 
Implementation 
level 
Total cost (realistic 
implementation) 
Cumulative cost 
(realistic 
implementation) 
Total DALYs 
averted (realistic 
implementation) 
16 
Malaria treatment: uncomplicated 
(children, >15 kg) 4  260  1,042,154  40% $1,907,299  $14,502,390  5,646  
17 
Malaria treatment: uncomplicated - 2nd 
line (children, <15 kg) 4  260  1,042,154  2% $530  $14,502,920  212  
18 
Malaria treatment: uncomplicated - 2nd 
line (children, >15 kg) 4  260  1,042,154  4% $2,474  $14,505,394  494  
19 
Malaria treatment: First trimester  W 
uncomplicated 5  198  304,921  33% $341,356  $14,846,750  36,248  
20 
Malaria treatment: Second trimester  W 
uncomplicated 5  198  304,921  67% $156,723  $15,003,473  72,497  
21 
Malaria treatment: pregnant women  W 
complicated 5  198  15,613  100% $139,592  $15,143,065  5,574  
 
22 Rotavirus vaccine 6  177  650,553  0% $0    $15,143,065  0    
23 
Management of pre-eclampsia 
(Magnesium sulphate) 6  168  20,022  80% $36,351  $15,179,416  427,775  
 
24 Tetanus toxoid (pregnant women) 7  149  918,437  84% $96,218  $15,275,634  87,025  
25 
Vitamin A supplementation in pregnant 
women 7  140  123,989  65% $81,378  $15,357,012  21,723  
 
26 Measles vaccine 9  106  650,553  99% $522,625  $15,879,637  105,593  
 
27 PMTCT 11  94  52,791  55% $331,814  $16,211,450  86,803  
 
28 Labour and delivery management 11  89  918,437  65% $832,934  $17,044,384  110,787  
 
29 Caesarean section (with complication) 12  86  5,051  100% $171,925  $17,216,309  137,341  
 
30 Management of obstructed labour 12  86  91,844  100% $1,099,805  $18,316,114  2,497,118  
 
31 Vaginal delivery, skilled attendance 12  83  918,437  65% $3,367,627  $21,683,741  43,446  
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# Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum 
Implementation 
level 
Total cost (realistic 
implementation) 
Cumulative cost 
(realistic 
implementation) 
Total DALYs 
averted (realistic 
implementation) 
 
32 Vaginal delivery, with complication 12  83  137,766  51% $409,984  $22,093,725  5,113  
33 
Households owning at least one 
ITN/LLIN 13  77  6,751,618  56% $7,706,339  $29,800,063  127,944  
 
34 Pregnant women sleeping under an ITN 13  77  1,469,499  100% $2,989,832  $32,789,895  49,638  
35 
Under five children who slept under 
ITN/LLIN 13  77  494,267  100% $1,005,632  $33,795,528  16,696  
 
36 Antenatal care (4 visits) 15  68  918,437  46% $5,109,715  $38,905,243  40,959  
 
37 Blood safety 15  66  39,554  100% $1,625,986  $40,531,229  11,866  
 
38 Male circumcision 22  45  4,073,429  12% $17,607,546  $58,138,776  4,756,136  
 
39 Newborn sepsis - Full supportive care 24  42  80,576  40% $166,877  $58,305,652  24,062  
40 
Antenatal corticosteroids for preterm 
labour 25  40  165,319  0% $0    $58,305,652  0    
 
41 Voluntary counselling and testing 25  40  8,030,614  15% $5,446,310  $63,751,962  25,065  
42 
Schistosomiasis mass drug 
administration 29  35  388,695  13% $9,949  $63,761,911  3,088  
 
43 Caesarean section 32  31  33,982  100% $671,704  $64,433,614  327,465  
 
44 Maternal sepsis case management 39  26  64,291  0% $0    $64,433,614  0    
 
45 Antibiotics for pPRoM 40  25  64,291  30% $11,639  $64,445,253  8,853  
46 
Management of severe malnutrition 
(children) 50  20  50,790  80% $1,949,487  $66,394,740  159,065  
47 
Interventions focused on female sex 
workers 51  20  23,478  30% $196,522  $66,591,262  48,405  
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# Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum 
Implementation 
level 
Total cost (realistic 
implementation) 
Cumulative cost 
(realistic 
implementation) 
Total DALYs 
averted (realistic 
implementation) 
48 
Interventions focused on men who 
have sex with men 51  20  33,758  5% $62,787  $66,654,049  11,600  
 
49 High cholesterol 68  15  222,947  1% $67,027  $66,721,076  9  
50 
Basic psychosocial support, advice, and 
follow-up, plus anti-epileptic 
medication 82  12  506,371  3% $37,978  $66,759,054  21  
 
51 Zinc (diarrhoea treatment) 99  10  7,455,177  0% $0    $66,759,054  0    
 
52 IPT (pregnant women) 110  9  734,750  100% $34,712  $66,793,766  99  
 
53 Condoms 127  8  8,030,614  47% $10,754,789  $77,548,555  226,463  
 
54 ORS 153  7  8,661,655  69% $646,592  $78,195,146  101,548  
 
55 Hypertension 159  6  845,659  10% $133,773  $78,328,919  4,449  
 
56 Treatment of depression 265  4  168,790  1% $3,316  $78,332,236  1  
 
57 Diabetes, Type I 296  3  23,063  15% $645,587  $78,977,823  4  
 
58 Diabetes, Type II 296  3  138,381  15% $631,593  $79,609,416  22  
 
59 ART for men 312  3  331,746  75% $15,960,590  $95,570,006  758,306  
 
60 ART for women 312  3  508,622  82% $26,668,904  $122,238,911  1,267,070  
 
61 Ischemic heart disease 453  2  128,130  15% $629  $122,239,540  1  
 
62 Treatment of bipolar disorder 557  2  523,250  3% $321,221  $122,560,760  6  
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# Intervention ICER [$] 
Population 
DALYs 
averted per 
1,000 
Cases per 
annum 
Implementation 
level 
Total cost (realistic 
implementation) 
Cumulative cost 
(realistic 
implementation) 
Total DALYs 
averted (realistic 
implementation) 
 
63 GIT, Intestine cancer 804  1  156  50% $1,355  $122,562,116  0  
 
64 Paediatric ART 892  1  106,677  25% $1,891,657  $124,453,773  384,498  
 
65 Cervical cancer (first line) 1,087  1  2,477  50% $80,812  $124,534,586  0  
 
66 Treatment of acute psychotic disorders 1,646  1  168,790  1% $9,581  $124,544,166  0  
 
67 Treatment of schizophrenia 1,646   1  2,363,066  14% $1,877,838  $126,422,004  53  
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3.5 Varying the scale of the EHP 
The exposition of the framework began by asking what the Malawian health care system is currently 
able to afford in terms of health-generating activities (health opportunity cost) and using that to 
identify an appropriate scale for the EHP.  This started with an estimate of the cost of averting an 
additional DALY of $61, an average across a range provided by recent work (Woods et al., In press) 
(Ochalek et al., 2015), and alternative estimates can be taken from this range.  For example, if a 
lower estimate of $38 per DALY is used to represent what the Malawian health care system is 
currently able to afford, fewer interventions would be included in the package (interventions 1 to 43 
in Table 4), and if a higher estimate is used, $120, more interventions would be affordable within the 
EHP (interventions 1 to 52 in Table 4). 
    
Exactly the same steps in the framework would be followed for these alternative estimates as 
previously: prioritising interventions within the EHP on the basis of net DALYs averted allowing for 
health opportunity cost; assessing the health implications of realistic levels of implementation 
resulting from intervention- and system-level constraints; prioritising potential intervention-specific 
implementation activities; assessing the value of system strengthening policies depending on how 
much of the budget underspend to partial implementation is used as the source of funding; and 
analysing the extent to which health outcomes would be improved by accepting partial 
implementation of existing interventions and using the underspend to fund an expansion of the 
package by adding previously excluded interventions. 
   
This is illustrated in Table 8 which shows, for the EHP budgets implied by the three alternative 
estimates of affordability (health opportunity cost), total spend and DALYs averted assuming 100% 
implementation and realistic levels given intervention and system constraints.  Table 8 also shows 
the magnitude of the budget underspend and the health forgone as a result of partial 
implementation of interventions, with the latter representing the maximum potential gains for 
implementation activities and system strengthening.  The table also shows the health outcomes that 
can be achieved, under the three alternative EHP budgets, if partial implementation due to 
constraints was accepted and the budget underspend was used solely to fund additional 
interventions to an extended package. 
 
Table 8 Three alternative scales of the EHP associated with different estimates of affordability (health 
opportunity cost) and implications for DALYs averted at full and realistic levels of implementation 
  
A B A-B C 
Full implementation Realistic implementation
16
 
Difference between full and 
realistic implementation Extended packaged 
How 
much 
can 
Malawi 
afford 
to pay 
to avert 
a DALY? Total spend 
Total DALYs 
averted Total spend 
Total DALYs 
averted 
Money left 
in the 
budget 
Maximum 
DALYs that 
could be 
averted by 
moving 
from 
realistic to 
full 
implementa
-tion Total budget Total DALYs 
 $38  
 $ 
257,409,698  48,803,384  
 $ 
64,433,614  11,194,346 
 $ 
192,976,084  
  
37,609,037  
 $ 
257,409,698  14,164,820 
 $61  
 $ 
264,526,889  49,445,122  
 $ 
66,654,049  11,422,269 
 $ 
197,872,840  
  
38,022,853  
 $ 
264,526,889  14,164,820 
 $120  
 $ 
274,318,115  49,690,912 
 $ 
66,793,766  11,422,398 
 $ 
207,524,349  
  
38,268,514  
 $ 
274,318,115  14,164,820 
                                                          
16
 Estimates of current levels of implementation are provided as part of Appendix 3. 
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3.6 Assessing the implications of donor-imposed constraints 
As discussed in Section 3.5, an important purpose of the framework is to expose the implications for 
health outcomes and budget underspend of partial implementation due to intervention- and 
system-level constraints.  The framework can also be used to consider the implications of another 
type of constraint  W those imposed by donors.  Donors contribute approximately 70% of funding to 
the Malawian health care system and consequently have considerable influence on resource 
allocation in the sector.  Donors have a range of objectives in the proposals they present to low-
income countries, and these will not necessary accord with working with the system to maximise 
population health subject to internal and donor funding.  In principle, donors may be willing to offer 
the system additional funding which can be used as the system considers appropriate.  Using the 
framework presented here, these additional resources could be devoted to the EHP to fund 
implementation activities, system strengthening or package expansion, with the objective of 
maximising health outcomes.  However, donors may impose constraints of how, and under what 
conditions, their additional funding is spent.  In negotiating with donors and communicating donor 
proposals to relevant stakeholders, policy makers will benefit from understanding the implications 
for population health of such constraints. 
 
To illustrate how the framework can provide this type of information to policy makers, four types of 
donor constraint are considered:  a requirement that a particular intervention is included in the EHP 
when the money for the intervention could have a bigger impact on health outcomes if spent 
elsewhere;  an offer to expand the package but restricted to a particular intervention when greater 
health outcomes could be generated by spending elsewhere; an offer to provide additional funding 
as long as this is matched by the Malawian Ministry of Health and conditional on the funding going 
on a particular intervention; and an offer to provide additional funding as long as this is matched but 
without a condition that the funding goes on a particular intervention.  The implications of each are 
considered below assuming a level of affordability reflecting a health opportunity cost of $61 per 
DALY averted and an implied budget of $264.5 million. 
 
3.6.1 Donor constraint I: forcing interventions into the EHP 
To illustrate the implications of the first constraint, it is assumed that a donor proposal has been 
accepted in the past which has resulted in an intervention being included in the EHP which would 
not otherwise have been selected on grounds of maximising gains in population health.  In other 
words, by imposing a constraint in return for funding, the donor has effectively forced an 
intervention into the EHP which resulted in other interventions being excluded which would have 
delivered greater gains in population health.   
 
dŽŝůůƵƐƚƌĂƚĞ ?ĂƐƐƵŵĞƚŚĂƚƚŚĞĚŽŶŽƌ ?ƐƉƌŽƉŽƐĂůǁĂƐƚŽƉƌŽǀŝĚĞ ?4.3 million to the EHP as long as this 
funding was directed to intervention 57 in Table 4, treatment for Type 1 diabetes.  As shown in Table 
4 and Figure 5, if the offer of funding had been unconditional, treatment for Type 1 diabetes would 
not have been included in the EHP.   As a result of the constraint, however, the equivalent amount of 
funding would have had to been taken away from interventions which would have been included 
under an unconditional funding offer.  Assuming interventions generating the least health 
improvement (least cost-effective) were removed first to make financial space for the diabetes 
treatment intervention, four interventions would be taken out, as shown in Table 9.  These four 
interventions together, assuming 100% implementation, would have a similar total cost as treatment 
for Type 1 diabetes ($4.3 million).  However, together, those four interventions would result in 
markedly more DALYs averted: 621,687 compared to 25 with diabetes treatment.  This means that 
the donor constraint resulted in 621,662 fewer DALYs averted than would have been the case if their 
offer of funding had not been conditional on the resources being devoted to treatment for Type 1 
diabetes. 
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Table 9 Health effects of donor constraints I: forcing an intervention into the EHP 
  Interventions cut 
Intervention 
forced in 
# 
45 46 47 48 45, 56, 47 & 
48 
50 
Intervention 
Antibiotics 
for 
pPRoM 
Management 
of severe 
malnutrition 
(children) 
Interventions 
focused on 
female sex 
workers 
Interventions 
focused on 
men who 
have sex 
with men 
Total 
interventions 
cut 
Type 1 
Diabetes 
treatment 
Cost 
 $ 
38,796  
 $ 
2,436,858  
 $ 
655,072  
 $ 
1,255,745  
 $ 
4,386,472  
 $ 
4,303,914  
DALYs 
averted 29,509 198,831 161,351 231,996 621,687 25 
 
In providing this type of information, the framework could have offered support to policy makers 
when the proposal was being considered.  In discussion with the donor, the Ministry of Health could 
have used the information to make clear the opportunity cost  W in terms of population health  W that 
was being imposed on Malawi.  This may have directed attention to those interventions (e.g. the 
four listed in Table 9 ?ĨŽƌǁŚŝĐŚƚŚĞĚŽŶŽƌ ?ƐĨƵŶĚŝŶŐĐŽƵůĚŚĂǀĞďĞĞŶƵƐĞĚƚŽŐƌĞĂƚĞƌĞĨĨĞĐƚ ?
potentially facilitating some form of negotiation. 
 
3.6.2 Donor constraint II: conditional expansion of the package 
The second donor constraint is similar to the first but can be thought of as a new proposal to 
augment the existing EHP budget, but only if the resources are devoted to a specific intervention.  
Assume the existing package relates to the $264.5 million and 48 interventions (at 100% 
implementation) shown in Table 4.  The donor proposal is to provide another $4.3 million (taking the 
total budget to $268.8 million), conditional on those resources being devoted only to a specific new 
intervention, treatment for Type 1 diabetes, which is not currently in the EHP.    
 
Table 10 shows the implications of this conditional package expansion.  As before, devoting $4.3 
million of additional funding to treatment for Type 1 diabetes would add 25 DALYs averted.  
However, if the offer of that additional funding had been unconditional, and the Ministry of Health 
had been free to use it to expand the package as it saw fit, the additional resources could have been 
devoted to those interventions generating the greatest additional impact in population health.  From 
the interventions detailed in Table 4, an unconstrained choice of how to spend the additional 
funding, with the purpose of health maximisation, would have added interventions 50, 51, 52 and 
54.  This would have resulted in 392,040 DALYs averted, 392,015 more than the intervention 
imposed by the donor.  Hence, the constraint imposed by the donor would result in an opportunity 
cost, in terms of population health, of 392,015 DALYs averted.  
52  CHE Research Paper 136 
 
Table 10 Health effects of donor constraints II: conditional expansion of the EHP 
# 
Other interventions currently not in the EHP  
Total 
 
  
50 51 52 54 57   
Intervention 
Basic 
psychosocial 
support, 
advice, and 
follow-up, 
plus anti-
epileptic 
medication 
Zinc 
(diarrhoea 
treatment) 
IPT (pregnant 
women) ORS 
Treatment 
for Type 1 
diabetes 
Health 
opportunity cost 
Cost 
 $      
1,265,925  
 $      
1,787,880  
 $      
34,712  
 $      
937,089  
 $      
4,025,606  
 $      
4,303,914    
DALYs 
averted 689 244,080 99 147,171 392,040 25 392,015 
 
As before, the information provided by the framework using available evidence would support 
decisions about an appropriate policy response to the donor offer.  In negotiations with the donor, 
the Ministry of Health can present the estimates with the aim of working with the donor to use the 
additional funding for those interventions with the greatest health impact.   One explanation for the 
donor making the additional funding conditional on it being used for a specific intervention is 
concern that corruption might result in those resources not being used appropriately if the offer was 
unconditional.   The assessment then becomes whether the anticipated loss in DALYs averted due to 
possible corruption under an unconditional offer is greater than the expected opportunity cost 
(392,015 DALYs averted ) that the framework indicates will be forced on the system by a conditional 
offer.  So the framework provides estimates to frame discussions between the government and 
donors. 
 
3.6.3 Donor constraint III: Donor matched funding conditional on funding of a particular      
intervention 
The third type of donor offer considered is one where additional funding is offered to augment the 
EHP budget, but this has to be matched by the Malawi government and the total additional funding 
needs to be devoted to a specific intervention that is currently not in the EHP, because it does not 
generate a sufficient gain in health outcomes for its cost (it is not cost-effective).   As for the last 
example, assume that the donor wants to make the proposal conditional on funding going to a 
particular intervention, treatment for Type 1 diabetes costing $4.3 million.  However, now the 
funder is only willing to fund $2.15 million of this, requiring the remainder to come from the EHP 
budget.  In order to free-up $2.15 million, the Ministry of Health will have to cut interventions and 
lose the health outcomes they achieve.  As before, assume the least cost-effective interventions are 
removed (i.e. those generating the least DALYs averted from their funding) as necessary to release 
the $2.15 million.  This involves cutting four interventions, with the freed-up funding, together with 
$2.15 million from the donor, being used to fund treatment of Type 1 diabetes.  The new total 
budget increases to $266.7 million compared to the original $264.5 million but, under the new 
arrangements, 480,004 fewer DALYs averted are generated, representing the health opportunity 
cost of the constraint imposed by the donor17. 
 
3.6.4 Donor constraint IV: Donor matched funding without conditions 
/ƚŝƐƵƐĞĨƵůƚŽĐŽŶƚƌĂƐƚƚŚĞƉƌŽƉŽƐĂůŝŶ^ĞĐƚŝŽŶ ? ? ? ? ?ǁŝƚŚŽŶĞǁŚĞƌĞƚŚĞĚŽŶŽƌ ?ƐŽĨĨĞƌŽĨĂĚĚŝƚŝŽŶĂů
matched funding is not conditional on the extra resources being devoted to a particular intervention 
not currently in the EHP.  In other words, to contrast it with a donor proposal of extra funding which, 
                                                          
17
 If the costs that are used to determine the size of the package are the same as (i.e., from the same source and equal) 
those that are used to calculate ICERs and net benefit, then forcing programs into the EHP (constraint I) will have a higher 
health opportunity cost than conditional donor matched funding.   This is discussed in Appendix 3.  See also footnote 13. 
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although needing matched funding from the EHP budget, can be used as considered appropriate by 
the Ministry of Health.  Assume the donor is again willing to provide $2.15 million with matched 
ĨƵŶĚŝŶŐĨƌŽŵƚŚĞ,WďƵĚŐĞƚ ?'ŝǀĞŶƚŚĞDŝŶŝƐƚƌǇ ?ƐŽďũĞĐƚŝǀĞŽĨŵĂǆŝŵŝƐŝŶŐŐĂŝŶƐŝŶƉŽƉƵůĂƚŝŽŶ
health, the absence of a condition means no existing interventions need to be removed from those 
funded by the original budget of $264.5 million.  Indeed, the additional $2.15 million from the donor 
can be used to add interventions to the package from those not currently funded (Table 4), but 
these can be selected in order to maximise gains in health outcomes from the additional resources.  
On that basis, it would be possible to add six interventions.  From the new effective budget of $266.7 
million and with these additional six interventions, total DALYs averted would be 49.4 million. 
   
The costs and health outcomes of these alternative donor offers are contrasted in Table 11.  The 
table shows the total budget and DALYs averted prior to the new donor offer, together with the 
costs and outcomes of the two matched funding offers.  As detailed in the last section, compared to 
the position pre-offer, the conditional matched funding donor proposal results in a reduction in 
DALYs averted of 480,004.  In contrast, matched funding of the same amount but without the 
condition of that funding being devoted to a specific intervention (here, Type 1 diabetes treatment), 
results in an additional 911 DALYs averted compared with the pre-offer position.  Therefore, if the 
donor decides to impose a condition to their matched funding that the resources are devoted to a 
particular intervention rather than leaving it unconditional, the health opportunity cost is 480,915 
DALYs averted. 
 
Table 11 Comparing the implications of two donor proposals with matched additional funding: one 
unconditional and one conditional on the extra resources being used to fund a specific intervention 
 
A B A-B C A-C (A-B)-(A-C) 
Original package 
(i.e., all 
resources 
marshalled and 
allocated by 
gov't to 
maximize 
population 
health) 
Matched 
conditional 
funding 
scenario 
Minimum 
health 
opportunity 
cost of matched 
conditional 
funding for 
Type 1 diabetes 
treatment 
Matched 
unconditional 
funding 
scenario 
Health benefit 
of matched 
unconditional 
funding 
compared to 
the original 
package 
Matched 
conditional 
versus 
unconditional 
funding 
Cost 
 $ 
264,526,889 
 $ 
  266,678,846    
 $ 
   266,678,846      
DALYs 
averted  49,445,122  
                   
48,965,118  480,004 49,446,033 -911  480,915 
 
Again, the magnitude of the impact on population health of imposing a condition is important to be 
able to communicate to the donor.  Of course, the degree of any health opportunity costs will 
depend on the details of the donor offers, but the analytical framework provides a means of 
establishing the health impact and can provide an essential support for negotiation.  In the context 
where a donor proposal includes a constraint that imposes considerable health opportunity costs 
(e.g. the matched conditional funding above), refusal of the offer may be entirely reasonable.  The 
ĨƌĂŵĞǁŽƌŬ ?ƐĞƐƚŝŵĂƚĞƐŽĨƚŚĞŚĞĂůƚŚŽƉƉŽƌƚƵŶŝƚǇĐŽƐƚƐƚŚĞƉƌŽƉŽƐĂůǁŽƵůĚŚĂǀĞŝŵƉŽƐĞĚƉƌŽǀŝĚĞĂ
valuable basis for explaining the decision to stakeholders. 
 
3.7 Allowing for additional objectives 
The framework presented here shows how the key concept of an empirical estimate of health 
opportunity costs, together with best evidence on the costs and health effects of potential 
interventions, can guide decisions about the EHP with an underlying objective of maximising 
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population health from available resources.  Of course there may be a range of other objectives that 
policy makers wish to factor into their resource allocation decisions and to influence which 
interventions are included in the package.  These objectives might include, for example, enhancing 
financial protection for vulnerable individuals and reflecting the contribution to net productivity of 
key groups in the population.   
 
How can the framework support decisions where a more complex set of objectives is operating?  It 
may be the case that considering a wider set of objectives makes no difference to resource 
allocation: the interventions that offer the greatest impact on population health are also the best 
available to satisfy other objectives.  This may often be the case, for example, when concerns for 
enhancing productivity are important in selecting interventions for the EHP because, in general, 
those interventions generating the greatest health outcomes, net of health opportunity costs, give 
the greatest opportunity for productive activities.  This will not always be the case, however, and 
trade-offs may be necessary  W that is, decisions that accept a reduction in aggregate population 
health in order to achieve one or more additional objectives such as enhancing financial protection.  
The framework presented here provides a valuable role in informing decisions characterised by 
trade-offs.  This is because it is able to quantify the magnitude of the health opportunity costs 
associated with a decision to select an intervention to further a wider set of objectives.  This 
provides policy makers with a basis to understand whether that trade-off is worth making and a 
means of communicating their ultimate decision to stakeholders.  
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4. Establishing and implementing an Essential Health Package 
This section provides some concluding comments on how the framework presented in Section 3 can 
be used by policy makers and enhanced over time. 
 
4.1 Ongoing use of the framework to inform Essential Health Package decisions 
As discussed in Section 1, to date the Malawian EHP has been reassessed every 5 years.  Following 
decisions being made about the 2016 EHP, there is a strong case for a more frequent consideration 
of the scale of the package, the interventions to be included and the funding of intervention-specific 
implementation activities and system strengthening.  This is because a number of the key 
considerations in developing the EHP are subject to rapid change over time.  The first of these 
relates to how much the Malawian health care system can afford to devote to EHP; the rate at which 
it is able to transform available resource into health gains for its population.  This is dependent on a 
range of factors including the total resources available from public finance and donors, the 
restrictions imposed on that funding (by donors in particular, but perhaps also central government), 
and the productivity of the health care system (itself a function of the strength of the system).   
 
A second consideration that is subject to change is the availability of new interventions to enhance 
health outcomes.  Additional investment opportunities can come through commercial development 
of new medical technologies, innovation in the organisation and delivery of health care, and 
research-based improvements in interventions and the system.  A third consideration that is subject 
to potentially rapid change is the acquisition cost of particular proprietary products as part of 
interventions (e.g. pharmaceuticals).  This can reflect factors such as competition from new market 
entries, the end of patent protection, and international political pressure.  A fourth consideration is 
rapid development of evidence about the costs and effectiveness of existing interventions, both 
those in the EHP and those not currently funded.  Although much of this evidence is international, it 
can have relevance to decisions in Malawi.   
 
Creating an ongoing process of updating the EHP that allows decisions to reflect the rapid change in 
these types of considerations provides the greatest opportunity to maximise the gains in health for 
the Malawian population. 
 
4.2 Building on available evidence 
The framework presented in Section 3 uses best evidence currently available.  This evidence relates 
to the rate at which the Malawian health care system can currently transform financial resources 
into gains in population health (the health opportunity cost), and to the costs and effects of the 
range of candidate interventions for the EHP.  The first type of evidence is currently limited to two 
recent pieces of work (Ochalek et al., 2015) (Woods et al., In press)  and is subject to uncertainty 
which should be reflected in how the framework is used (i.e. by employing different scenarios 
regarding the estimated health opportunity cost as shown in Section 3.5).  Ongoing international 
work to provide estimates of health opportunity costs relevant to individual jurisdictions is central to 
evidence-based resource allocation decisions, and providing a more precise estimate for Malawi is 
likely to be a priority research area.    
 
The evidence on the costs and effects of potential EHP interventions used in the framework to date 
needs further development.  Other sources of data are likely to be avĂŝůĂďůĞƐŚŽƌƚůǇ ?Ğ ?Ő ?ƚŚĞt,K ?Ɛ
full-sectoral CHOICE analysis for Malawi) and these should be included.  Over time the richness of 
the available data should improve.  One aspect of this that will be potentially important is to be able 
to distinguish the intervention-specific cost of adding an intervention to the package from the cost 
of those resources that are shared across several interventions.  This may be important when, for 
example, a decision is being considered to remove an intervention from the EHP: some or all of the 
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former may be released if the intervention is taken out of the package, but the latter will not.  
Currently that distinction is not possible from the data available. 
 
4.3 Analysis versus decision making 
It is important to emphasise that the analytical framework and the results it has generated so far are 
not dictating a list of interventions to include in the EHP.  Rather, this analysis is intended to support 
a decision making process within the Ministry of Health.  This is sometimes referred to as the 
distinction between assessment (analysis based on available evidence) and appraisal (decision 
making).  Decision making needs to be able to interact with the analytical framework in a number of 
ways.  This includes providing clarity about the scope of decisions that are being addressed  W in 
particular, the balance between selecting interventions for the EHP, making investment decisions for 
intervention-specific implementation activities and system strengthening, and responding to funding 
proposals from donors.  There is also a key role for decision makers in providing information about a 
wider set of objectives that might be relevant to decisions other than gains in population health.  
Decision makers may also have relevant information on intervention- and system-level constraints 
that might exist and their implications for plausible levels of implementation.  Policy makers may 
also provide valuable input into establishing the best available evidence relating to particular 
interventions, in particular the cost of delivery. 
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Appendix 1. Review of the 2011 Essential Health Package 
Alongside the introduction of a Sector Wide Approach (SWAp) in the health sector, Malawi 
introduced its first Essential Health Package (EHP) in 2004.  EHP services were to be provided free of 
charge to patients at government health care facilities as well as some other facilities through 
agreements.  A second EHP was introduced from 2011-2016.  It expanded upon the package defined 
in 2004 to reflect that disease patterns and available resources had changed and to take into 
account new technologies that had been introduced (Phoya et al., 2010).  While the 2004-2010 EHP 
focused on reducing infant and under five mortality, improving maternal mortality rates, preventing 
HIV and reducing population growth,  the 2011-2016 package recommended gradual expansion to 
ŝŶĐůƵĚĞ ?ĨŽƌĞǆĂŵƉůĞ ? ?ĐŽƐƚ-ĞĨĨĞĐƚŝǀĞ ? interventions for non-communicable diseases and a package of 
 ?ŚŝŐŚůǇĐŽƐƚ-ĞĨĨĞĐƚŝǀĞ ? surgical procedures (Ministry of Health, 2012).   
 
The 2011 EHP was based upon two main criteria: BoD and cost-effectiveness (Phoya et al., 2010).  
Burden of disease evidence was based upon estimates from the College of Medicine, which updated 
the 2002 burden of disease estimates for individual countries produced by the World Health 
Organization (WHO) Global Burden of Disease (GBD) in 2002 and updated in 2004, as well as the 
STEPS study on non-communicable diseases (Mathers, Boernma and Ma Fat (2008) and Phoya et al. 
(2010)).   
 
Diseases were ranked by the disability adjusted life years (DALYs) associated with them.  Thirteen 
conditions were named as contributing most heavily to the BoD in Malawi: HIV/AIDS, ARI, malaria, 
diarrhoeal diseases, perinatal conditions, non-communicable diseases (NCDs), tuberculosis, 
malnutrition, cancers, vaccine preventable diseases, mental illness and epilepsy, neglected tropical 
diseases (NTDs), and eye, ear, and skin infections.  Nine of these were included in the first EHP that 
was part of the Program of Work (PoW) 2004-2010; cancers, mental illness and epilepsy, and NTDs 
being new additions that were also included in the 2011-2016 EHP (Ministry of Health, 2012).   
 
Burden of disease provides a systematic and transparent criterion for resource allocation.  Indeed, 
the scale of the health gains associated with implementing an intervention depend upon the size of 
the population that would benefit, and burden of disease can be a good proxy measure for this.  
Although it provides useful information alongside estimates of cost effectiveness, it should not be 
used as a criterion itself.  Burden of disease has implications for the budget, as interventions for 
diseases with high burden may have large budget impacts, in which case the expected health 
opportunity costs of a proposed intervention with high budget impact should be estimated using a 
lower rate of financial resources spent to achieve a unit of health gain, since large budget impacts 
displace more productive activities.  Ultimately, it is the impact of different interventions that needs 
to be known, not the impact of different diseases (Williams, 1999).  
 
Using burden of disease, 56 interventions were identified and evaluated for cost-effectiveness.  
Cost-effectiveness estimates were obtained from Disease Control Priorities Second Edition (DCP2), 
and were not specific to Malawi.  Interventions were determined to be cost-effective if they had an 
ICER at or below $150 per DALY averted.  This measure of the opportunity cost of health spending 
lacks an empirical foundation, and likely represents an overestimate of the effect of spending in the 
health sector on health outcomes.  Using a measure that is too high leads to net losses in population 
health as the health opportunity costs of interventions are underestimated. 
 
Figure A1 shows the 56 interventions that were considered for the 2011-2016 EHP.  The 
interventions are listed in order of disease burden (e.g. intervention 1 is for HIV/AIDS, which 
contributes the most to BoD in Malawi) (Bowie and Mwase, 2011).  
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Figure A1 Burden of disease and cost-effectiveness of interventions in Malawi (Ministry of Health, 2012) 
 
A number of interventions are cost-effective according to the $150/DALY averted criterion used and 
have a high burden of disease, but were not included in the package.  Technical Working Groups 
were tasked with appraising the potential interventions and deciding which were included in the 
package.  Practical reasons are given for some of these choices and the authors argue that a 
rationale exists for all.  One example is intermittent prophylaxis for malaria, which although it is cost-
effective, it is not yet part of the strategy of the Malaria Unit (Ministry of Health, 2012).  (For 
additional rationales, see DCP3 Working Paper #9.)  However, the health opportunity cost of these 
decisions was not explicitly valued to inform the decision making process. 
 
Although the 2004 and 2011 packages were designed to allocate only the portion of the budget 
designated to the EHP, the package was estimated to cost 83-132% of total health expenditure 
(THE).  Overestimating the ability of the health care system to pay for the package results in net 
losses in population health.  Interventions are initially financed as if enough resources available, but 
the budget is eventually exhausted before all the promised interventions are provided in full.  As a  
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result, the budget is spent on a mix of all EHP interventions and not necessarily the most cost-
effective ones.  Lower health gains than could have been achieved by the budget are actually 
achieved. 
 
Table A1 Per capita EHP cost and actual health spending 
EHP Year EHP cost pc 
Total Health 
Expenditure 
(THE) pc in US$ 
EHP cost pc as a % 
of THE pc 
1 (2004-2010) 2004 $17.53 (a) $16.32 107% 
1 (2004-2010) 2005 $17.53 (a) $17.49 100% 
1 (2004-2010) 2006 $17.53 (a) $21.06 83% 
1 (2004-2010) 2007 $17.53 (a) $17.74 99% 
1 (2004-2010) 2008 $28.56 (b) $25.36 113% 
1 (2004-2010) 2009 
 
$28.73 
 1 (2004-2010) 2010 $44.40 (b) $33.57 132% 
2 (2011-2015) 2011 $44.40 (b) $38.80 114% 
     Sources: 
    (a) A Joint Programme of Work for a Health Sector Wide Approach (SWAp) 2004 - 2010 (Ministry of 
Health, 2004). 
(b) Ministry of Health, Malawi 
(c) WHO Global Health Expenditure database (World Health Organization, 2016). 
 
In summary, the 2011 EHP failed to deliver a package that maximized population health.  It put forth 
two criteria for determining which interventions were included in the package, burden of disease 
and cost-effectiveness.  Neither was perfectly adhered to and ultimately decisions around what to 
include incorporated additional objectives and were not fully transparent.  The use of $150 per DALY 
for evaluating health opportunity costs is likely to underestimate said opportunity costs and burden 
of disease is not in itself a criterion under which health will be maximised. 
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Appendix 2. Measures of cost-effectiveness 
The results of economic evaluation are commonly summarised as incremental cost-effectiveness 
ratios (ICERs), which provide a useful summary of how much additional resource is required to 
achieve a measured improvement in health (e.g. the additional cost per DALY averted), or how much 
health is delivered for an amount of additional resource (e.g. the DALYs averted per $1,000).  
However, to decide whether the intervention will improve health outcomes overall (and should be 
regarded as cost-effective), a comparison is required with an assessment of the likely health 
opportunity costs. 
 
A2.1 Problems with cost per DALY measures (one active treatment) 
An assessment of health opportunity costs makes it possible to express cost-effectiveness as the 
expected additional net health or net monetary benefit offered.  It indicates the scale of the 
potential overall impact of ensuring an intervention is fully implemented and identifies the amount 
of resource that might be devoted to these efforts. 
 
Even when there is only one active treatment, a focus on cost per DALY does not necessarily indicate 
which programmes ought to be prioritised for implementation efforts because cost per DALY does 
not indicate the scale of the potential overall impact.  The examples of technologies T1  WT4 in 
Section 2 are reproduced in Table A2.  In this example the intervention with the lowest cost per 
DALY (T4) also offers the greatest value (expressed as net DALY averted or $ value to the health care 
sector (HCS)) and the intervention with the next highest cost per DALY (T1) offers the lower value. 
 
Table A2 Prioritising implementation efforts (same population) 
Technology 
ICER 
($/DALY) 
DALYs averted 
(,000 DALYs) 
HCS 
Costs 
Net DALYS averted 
(,000 DALYs) $ Value to HCS 
T3 $300 200 $60m -100 -$20m 
T2 $200 200 $40m 0 0 
T1 $100 200 $20m 100 $20m 
T4 -$100 200 -$20m 300 $60m 
 
However, these examples are a very special case where the health benefit per patient is the same (2 
DALYs averted) for each intervention and the population of patients that can benefit from each are 
also the same (100,000 for each).  Even when the per patient health benefit remains the same, any 
differences in the size of the population that can benefit will mean that cost per DALY measures will 
not necessarily rank interventions by the value they offer and will not indicate the scale of value (in 
DALYs or $).   
 
This is illustrated in Table A3 which uses the same interventions (T1-T4) with the same estimate of 
health opportunity costs ($200 per DALY), the same per patient benefits, and the same total 
population (400,000).  The only difference is that the population that can benefit differs by 
intervention (T1=300,000, T2=80,000, T3=10,000 and T4=10,000).  Intervention T1, which has a 
higher cost per DALY than T4, offers the greatest value (expressed as net DALY averted or $ value to 
the HCS).  The cost per DALY summary measures are the same in Tables A2 and A3, but the priorities 
for implementation efforts differ, as does the importance of considering specific constraints.  In 
addition, the amount the HCS might devote to dealing with intervention specific constraints or 
system weaknesses also differs.  Therefore, cost per DALY measures alone cannot be used to 
prioritise implementation efforts and system strengthening.  An assessment of health opportunity 
costs makes it possible to estimate the scale of the potential impacts on overall health outcomes of 
implementation efforts in a way that reporting ICERs and categorical judgments about cost-
effectiveness cannot. 
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Table A3 Prioritising implementation efforts (different population) 
Technology 
ICER 
($/DALY) 
DALYs averted 
(,000 DALYs) 
HCS 
Costs 
Net DALYS averted 
(,000 DALYs) $ Value to HCS 
T3 $300 20 $6m -2 -$10m 
T2 $200 160 $32m 0 0 
T1 $100 600 $60m 300 $300m 
T4 -$100 20 -$2m 30 $10m 
 
A2.2 Problems with cost per DALY measures (multiple alternatives) 
When there is more than one active intervention available within a programme (for a specific 
population with a particular indication) the use of cost per DALY is even more problematic.  An 
assessment of health opportunity costs which enables measures of the net DALYs averted and $ 
value to HCS overcomes these difficulties. 
 
Informing a decision requires identifying the possible alternative courses of action that could be 
taken to improve the health of patients who face a choice between mutually exclusive alternatives 
(i.e. either/or decisions), including not offering active treatment.  Often, there is more than one 
active alternative available (alternatives include the different combinations or sequences of 
treatment and different ways in which interventions can be used).  In these circumstances there are 
multiple pairwise comparisons that can be made, each providing different incremental costs and 
DALYs averted, resulting in a number of different cost per DALY ratios that could be reported.  This is 
illustrated in Table A4 and graphically in Figure A2, where there are four alternative active treatment 
strategies (T1-T4), plus no treatment (T0), for a specific indication and patient population. 
 
Table A4 Multiple alternatives and multiple cost per DALY measures 
Alternative 
interventions 
DALYs 
averted pp 
HCS costs 
pp 
Cost per DALY averted compared to: 
No treatment Next most 
effective 
EĞǆƚ ?ďĞƐƚ ?
(dominance) 
EĞǆƚ ?ďĞƐƚ ?
(extended 
dominance) 
T0 0 $0 - - - - 
T1 1 $100 $100 $100 $100 $100 
T2 2 $600 $300 $500 $500 - 
T3 3 $1,800 $600 $1,200 - - 
T4 4 $1,000 $250 -$800 $200 $300 
 
These are just some of the pairwise comparison than can be made. The question is which 
ĐŽŵƉĂƌŝƐŽŶƐĂƌĞĂƉƉƌŽƉƌŝĂƚĞ ?dŚĞĐŽŵƉĂƌŝƐŽŶƐŚŽƵůĚďĞǁŝƚŚƚŚĞŶĞǆƚ ?ďĞƐƚ ? ?ŵŽƐƚĐŽƐƚ-effective) 
alternative.  Unless comparisons are made with the next best alternative, an intervention might 
appear worthwhile simply because it has been compared to an alternative which itself is not 
worthwhile (anything can look good if compared to something sufficiently bad).   
 
For example, T4 appears cost saving when compared to T3, but T3 itself is not worthwhile because it 
is less effective and more costly than T4 (T3 is strongly dominated; it lies to the north west of T4 in 
Figure A2).  Once T3 is removed from consideration T4 appears just worthwhile when compared to 
d ? ?ĂƚĂ ?ƚŚƌĞƐŚŽůĚ ?ŽĨ ? ? ? ?ƉĞƌ>zƐ ? ?,ŽǁĞǀĞƌ ?d ?ŝƚƐ ůĨŝƐŶŽƚǁŽƌƚŚǁŚŝůĞ ? ? ? ? ?ƉĞƌ>z
ĐŽŵƉĂƌĞĚƚŽd ? ? ?/ŶĨĂĐƚ ?d ?ǁŽƵůĚŶĞǀĞƌďĞĐŚŽƐĞŶŝƌƌĞƐƉĞĐƚŝǀĞŽĨǁŚŝĐŚ ?ƚŚƌĞƐŚŽůĚ ?ƌĞĨůĞĐƚĞĚ
health opportunity costs.  For example, at $500 per DALY, T2 would be regarded worthwhile 
compared to T1 but a decision-maker should not be satisfied with T2 because T3 would offer greater 
health improvements at a cost per DALY that would also be regarded as worthwhile.  Therefore, T2 
will never be chosen (it is extendedly dominated).  This is also illustrated graphically in Figure A2.  
Point T2 lies to the north-west of the part of the line that joins T4 and T1. T2 can be thought of as 
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ďĞŝŶŐƐƚƌŽŶŐůǇĚŽŵŝŶĂƚĞĚďǇƐŽŵĞĐŽŵďŝŶĂƚŝŽŶŽƌ ?ŵŝǆƚƵƌĞ ?ŽĨd ?ĂŶĚd ? ?dŚŝƐƚǇƉĞŽĨ ?ŵŝǆƚƵƌĞ ?ŝƐ
often not regarded as feasible (e.g. due to equity constraints), so T2 remains extendedly rather than 
strongly dominated but importantly it will never offer the highest net DALYs averted (see Table A5). 
 
Figure A2 Multiple mutually exclusive alternatives 
 
The difficulties of using ratios based on pairwise comparisons to describe the cost-effectiveness of 
multiple alternatives can easily be overcome once an assessment of health opportunity costs has 
been made, because this allows the value of each mutually exclusive alternative to be expressed in 
terms of net DALY averted or the $ value to the HCS.  This is illustrated in Table A5, assuming a 
population of 100,000 and health opportunity costs of $200 per DALY.  It is T1 which offers the 
highest, and positive, net DALY averted (and $ value of HCS).  Therefore, if the HCS was able to 
afford $200 per DALY, this programme should be covered in an EHP but the intervention included to 
deliver this programme should be restricted to T1. 
 
Table A5 Choosing between multiple alternatives 
Alternative 
interventions 
DALYs averted 
(,000 DALYs) 
HCS costs 
Net DALYs averted 
(,000 DALYs) 
$ value to HCS 
T0 0 0 0 0 
T1 100 $10m 50 $10m 
T2 200 $60m -100 -$20m 
T3 300 $180m -600 -$120m 
T4 400 $100m -100 -$20m 
 
In summary: 
 
i) The mutually exclusive alternative intervention which should be included in an EHP is the one 
with highest value (net DALYs averted or $ value to the HCS).   
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ii) If T0 (no treatment) is the highest (all others reduce health outcomes overall) then the 
programme (the collection of mutually exclusive interventions) should not be covered.   
 
iii) There is no need to consider which pairwise comparisons should be made or identify which are 
strongly or extendedly dominated because they will never offer the highest value (net DALYS or 
$ value to the HCS).   
 
iv) Whichever pairwise comparison is made when reporting cost per DALY - so long as it is possible 
to recover the total DALYs averted and the total HCS costs for the target population - then, when 
combined with an assessment of health opportunity costs, this pairwise comparison can be used 
to inform which programmes should be covered in an EHP and which interventions within each 
programme should be included. 
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Appendix 3. Guide to the living library of data for use in the development of an 
Essential Health Package 
The development of an Essential Health Package (EHP), aligned to the principles set forth in Section 
2, requires reliable data.  This appendix describes the living library of data created for this purpose 
and provides a guide to its continued use and maintenance.  The appendix is structured in five 
sections: 
 
1. Data requirements 
2. Data used for the development of the 2011 EHP 
3. Identification of additional data 
4. Data conversion and use 
5. Summary of data collected and future use by Ministry of Health and partners 
 
A3.1 Data requirements 
The key data needed for each intervention in order to consider it for inclusion within the package 
are those that enable comparisons of cost-effectiveness and calculation of net benefits.  These are: 
 
1. Estimates of cost-effectiveness  
2. >zƐĂǀĞƌƚĞĚĐŽŵƉĂƌĞĚƚŽĂ ?ĚŽŶŽƚŚŝŶŐ ? strategy 
3. Number of cases (or patients) and realistic coverage levels 
4. Per case (or patient) costs 
 
Some of the data are more difficult to obtain than others, but all are necessary to quantify 
appropriately the health benefits and opportunity costs associated with possible packages that could 
be provided. 
 
A3.2 Data used for the development of the 2011 Essential Health Package 
The process for obtaining data for the 2016 revision of the EHP involved first reviewing the data 
sources used to develop the 2011 EHP for appropriateness and availability.  See Appendix 1 for 
further details on the review of the 2011 EHP.  The 2011 EHP relied on estimates of cost-
effectiveness from one source: Disease Control Priorities Project second edition (2006) economic 
evaluation studies in low- and middle-income countries (DCP2).  Although DCP2 provides estimates 
for a comprehensive list of potential interventions, the underlying cost and DALYs averted are 
generally not included.  As shown in Section 2 estimates of cost-effectiveness alone are an 
inadequate basis for decision making18.  Additionally, as DCP2 was published in 2006 and drew upon 
a number of studies published well prior to this, many studies upon which the estimates were based 
are now out of date and more recent studies with relevant data were likely to also be available.  
DCP2 was therefore deemed not to be an appropriate source of estimates for the 2016 EHP revision.  
DCP is currently being updated in a 3rd edition with more recent cost-effectiveness estimates.  If the 
underlying cost and effectiveness data are also published, this could be a useful source from which 
to draw upon in future when these are made publicly available. 
 
A3.3 Identification of additional data 
The World Health Organization Choosing Interventions that are Cost-Effective (WHO-CHOICE) team 
was identified as a good candidate for providing the necessary data.  The WHO-CHOICE team are 
currently undertaking comprehensive analyses of the cost-effectiveness of interventions relevant to 
the new Malawian EHP.  However, despite requests made to both DCP and WHO-CHOICE teams, 
these updated estimates were not made available by the deadline set for the EHP revision. 
                                                          
18
  In the absence of any additional data reliable ICERs would still be better than nothing to form an EHP, but where 
additional data exists this should be incorporated for better decision making. 
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Alternative sources of cost-effectiveness were therefore required.  The Tufts Global Health Cost-
Effectiveness Analysis Registry was identified as a comprehensive database of peer-reviewed studies 
containing cost-per-disability adjusted life year (DALY) estimates on global health.  The database 
included 484 cost-effectiveness studies applied to low- and middle-income settings.  These studies 
were screened, and those containing estimates relevant to Africa and, where there were multiple 
studies of the same interventions, the more recent and/or those more applicable to Malawi were 
prioritised.  The database included 16 WHO-CHOICE studies published since 2005 and 26 other 
studies, resulting in 42 studies that were reviewed in depth.  This was supplemented by systematic 
review of the cost effectiveness of vaccines that was also found, and for which the original studies in 
the bibliography were reviewed. 
 
The review of cost-effectiveness studies was undertaken under very tight time and resource 
constraints.  It was pragmatic and was neither exhaustive nor systematic.  The framework for the 
EHP should continue to be populated on an ongoing basis by the Ministry of Health and partners to 
ensure the choice of interventions reflects best available international evidence on the cost-
effectiveness as it can be applied to the Malawian context.  The establishment of processes and 
systems to ensure this occurs is the responsibility of the Ministry of Health and its core partners. 
 
A3.4 Data conversion and use 
From the papers, identified data on items 1-4 listed above was extracted.  Further detail about how 
these data were converted for use the development of the 2016 EHP are given below. 
 
A3.4.1 Estimates of cost-effectiveness 
The constituent parts of the cost-effectiveness ratio are costs and DALYs averted.  (See Appendix 2 
for further discussion of methods.)  In order to compare cost-effectiveness ratios it is necessary that 
they are in the same currency.  Estimates of cost-effectiveness from the papers were reported in 
various currencies (e.g. 2000 Int$, 2008 US$, etc.).  Where costs were given in Int$ these were first 
converted into US$ using the appropriate years ? PPP exchange rate for Malawi provided by the 
World Bank and then inflated to 2016 US$ using inflation rates from US Inflation Calculator19.  Table 
A6 provides the rates used.  The cost-effectiveness ratios were then recalculated using the 2016 US$ 
cost and the DALYs averted as reported by the original source.  Due to the currency conversion 
applied to the numerator of the ratio, many of the cost-effectiveness ratios used in this report are 
not the same as those reported by the study from which they are drawn, but instead reflect current 
costs estimated to be incurred in Malawi.  It is assumed that evidence on clinical effectiveness 
generalises to Malawi.  This facilities comparability of cost-effectiveness studies and enables 
estimation of net benefits in the Malawian context. 
 
Ideally, estimates of cost-effectiveness would be specific to Malawi using both costs and DALYs 
averted from studies in Malawi.  This is discussed in more detail in Section 3.5. 
 
 
 
 
 
 
 
 
 
 
 
                                                          
19
  World Bank PPP conversion rates: http://data.worldbank.org/indicator/PA.NUS.PPP; US Inflation Calculator: 
http://www.usinflationcalculator.com/  
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Table A6 Currency conversion rates 
Malawi 2000 PPP conversion factor 0.223 
Cumulative inflation (year to 2016) 
2000 0.395 
2001 0.357 
2002 0.335 
2003 0.306 
2004 0.272 
2005 0.230 
2006 0.192 
2007 0.159 
2008 0.116 
2009 0.120 
2010 0.102 
2011 0.068 
2012 0.046 
2013 0.031 
2014 0.015 
2015 0.014 
 
 
A3.4.2 >zƐĂǀĞƌƚĞĚĐŽŵƉĂƌĞĚƚŽĂ ?ĚŽŶŽƚŚŝŶŐ ? strategy 
Data on DALYs averted per patient for each intervention were used directly from papers where 
these were provided.  In other cases, DALYs averted were estimated using additional data from the 
paper (e.g. patient population, per patient costs and cost effectiveness ratios).  See Berry et al 
(2010), Roberts et al (2016), Vassall et al (2014) and Wilford et al (2012) in Table A7. 
 
WHO-CHOICE papers typically give cost-effectiveness estimates for World Health Organization 
regions.  To move from the estimate of DALYs averted in the region to DALYs averted per year in 
Malawi the following additional data was required:  
 
x ݌݋݌ோ population of the region (i.e. AFR-E or AFR-D) 
x ݌݋݌ெ population of Malawi 
x ݌݋݌ெವ  population of patients in Malawi with disease D 
x   ܲ  population of Malawi as a proportion of the population of the region  
  (i.e.,݌݋݌ெ௔௟௔௪௜ ݌݋݌௥ ?  ) 
 
The data used on the population from the region and the population of Malawi was from the World 
Bank20.  The estimates of the Malawi patient population for conditions were obtained from the 
Palladium Group and Clinton Health Access Initiative (CHAI) Malawi country office, for which 
assistance is greatly appreciated.  Table A7 lists the format of the data and how it was converted for 
use in the development of the EHP for each source from which data was collected. 
 
 
 
 
 
                                                          
20
  World Bank population data: http://data.worldbank.org/indicator/SP.POP.TOTL  
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Table A7 Data sources 
Source Costs as given 
by source ࡯ࡿ Currency DALYs averted as given by 
source ࡰࡿ Region ࡾ Method for calculating costs for Malawi ࡯ࡹ Method for calculating DALYs averted for 
Malawi 
Adam et al. (2005) Yearly costs in 
millions 
2000 Int$ Yearly DALYs 
averted 
(millions) 
AFR-E ܥெൌ ܥௌ כ ܲכ ݈݈݉݅݅݋݊ ܦெൌ ܦௌ כ ܲכ ݈݈݉݅݅݋݊ 
Alistar et al. (2014) Per patient 
costs 
2014 US$ Per patient 
QALYs 
South 
Africa 
ܥெൌ ܥௌכ ݈݈݉݅݅݋݊Ȁ݌݋݌ௌ௢௨௧௛஺௙௥௜௖௔  
ܦெൌ ܦௌכ ݈݈݉݅݅݋݊Ȁ݌݋݌ௌ௢௨௧௛஺௙௥௜௖௔  
Baltussen et al. 
(2012) 
Yearly costs in 
millions for 
62,000 
patients 
2000 Int$ Yearly DALYs 
averted 
(millions) for 
62,000 
patients 
AFR-E ܥெൌ ܥௌ כ ݈݈݉݅݅݋݊ ? ?ǡ ? ? ?כ ݌݋݌ெವ  
ܦெൌ ܦௌ כ ݈݈݉݅݅݋݊ ? ?ǡ ? ? ?כ ݌݋݌ெವ  
Berry et al. (2010) Net cost using 
GAVI alliance 
prices 
(Intervention 
cost  W 
Treatment 
cost) for a 
birth cohort 
of 582,211 
2008 US$ Total DALYs 
averted for a 
birth cohort of 
582,211 
Malawi ܥெ ൌ ܥௌ ܦெ ൌ ܦௌ  
Ciaranello et al. 
(2015) 
Discounted 
per patient 
lifetime costs 
(3%) 
2013 US$ Discounted 
per patient 
lifetime DALYs 
averted (3%) 
Zimbabwe ܥெ ൌ ܥௌ כ ݌݋݌ெವ  ܦெ ൌ ܦௌ כ ݌݋݌ெವ  
Chisholme et al. 
(2012)  
Annual cost 
per million 
population in 
millions 
2000 Int$ Annual effect 
(DALYs saved) 
per million 
population 
AFR-E ܥெൌ ܥௌ כ ݌݋݌ோ כ ܲ ܦெൌ ܦௌ כ ݌݋݌ோכ ܲȀ݈݈݉݅݅݋݊ 
Darmstadt et al. 
(2005) 
 
 
Millions  2000 Int$ DALYs averted 
(millions) 
AFR-D ܥெൌ ܥௌ כ ݈݈݉݅݅݋݊כ ݌݋݌ெ݌݋݌ோ  
ܦெൌ ܦௌ כ ݈݈݉݅݅݋݊כ ݌݋݌ெ݌݋݌ோ  
Morel et al. (2005) 
(online) 
Cost per year 
in millions per 
one million 
population 
[i.e. cost per 
capita] 
2000 Int$ DALYs averted 
per year per 
one million 
population 
AFR-E ܥெ ൌ ܥௌ כ ݌݋݌ெ  ܦெൌ ܦௌכ ݌݋݌ெȀ݈݈݉݅݅݋݊ 
Creese et al. 
(2002) 
Unit cost 2000 US$ Effectiveness, 
DALYs gained 
per unit 
Kenya, 
Tanzania 
ܥெ ൌ ܥௌ כ ݌݋݌ெವ  ܦெ ൌ ܦௌ כ ݌݋݌ெವ  
Gaziano et al. 
(2014) 
 
 
1. Appx cost 
per patient  
2. Total cost 
2012 US$ Total DALYs 
averted 
South 
Africa 
ܥெൌ ܥௌଵ כ ݌݋݌ெವ  ܦெൌ ܥௌଵܥௌଶ כ ܦௌכ ݌݋݌ெವ  
Hogan et al. 
(2005) 
 
 
Yearly costs in 
millions 
2000 Int$ Yearly DALYs 
averted 
(millions) 
AFR-E ܥெൌ ܥௌ כ ܲכ ݈݈݉݅݅݋݊ ܦெൌ ܦௌ כ ܲכ ݈݈݉݅݅݋݊ 
Kapoor et al. 
(2016) 
 
Net cost per 
individual 
2014 US$ DALYs per 
individual 
India ܥெ ൌ ܥௌ כ ݌݋݌ெವ  ܦெ ൌ ܦௌ כ ݌݋݌ெವ  
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Source Costs as given 
by source ࡯ࡿ Currency DALYs averted as given by 
source ࡰࡿ Region ࡾ Method for calculating costs for Malawi ࡯ࡹ Method for calculating DALYs averted for 
Malawi 
Lo et al. (2015) 
 
 
 
1. Appx cost 
per patient  
2. Total cost 
2014 US$ Total DALYs 
averted 
Cote 
D'Ivoire 
ܥெ ൌ ܥௌ כ ݌݋݌ெವ  ܦெൌ ܥௌଵܥௌଶ כ ܦௌכ ݌݋݌ெವ  
Revill et al. (2015) 
 
 
 
Cost saving 
per patient 
year 
2013 US$ DALYs averted 
per patient 
year 
Uganda, 
Zimbabwe 
ܥெ ൌ ܥௌ כ ݌݋݌ெವ  ܦெ ൌ ܦௌ כ ݌݋݌ெವ  
Robberstadt et al. 
(2004) 
 
Per patient 2001 US$ Per patient Tanzania ܥெ ൌ ܥௌ כ ݌݋݌ெವ  ܦெ ൌ ܦௌ כ ݌݋݌ெವ  
Roberts et al. 
(2016)  W 
emergency 
caesarean 
 
Not provided, 
calculated as 
ICER*DALYs 
averted 
2012 US$ Total DALYs 
averted for 
196 patients 
Zambia ܥெ ൌ ܥௌ כ ݌݋݌ெವ  ܦெ ൌ ܦௌ כ ݌݋݌ெವ  
Roberts et al. 
(2016)  W elective 
caesarean 
Not provided, 
calculated as 
ICER*DALYs 
averted 
2012 US$ Total DALYs 
averted for 11 
patients 
Zambia ܥெ ൌ ܥௌ כ ݌݋݌ெವ  ܦெ ൌ ܦௌ כ ݌݋݌ெವ  
Tan-Torres Edejer. 
et al (2005) 
 
 
Yearly cost in 
millions 
2000 Int$ DALYs averted 
per year 
(millions) 
AFR-E ܥெൌ ܥௌ כ ݈݈݉݅݅݋݊כ ݌݋݌ெ݌݋݌ோ  
ܦெൌ ܦௌ כ ݈݈݉݅݅݋݊כ ݌݋݌ெ݌݋݌ோ  
Uthman et al. 
(2011) 
Cost 2008 US$ DALYs Sub-
Saharan 
Africa 
ܥெ ൌ ܥௌ כ ݌݋݌ெವ  ܦெ ൌ ܦௌ כ ݌݋݌ெವ  
Vassall et al. 
(2014) 
Total cost 2011 US$ DALYs averted 
from 2004-
2008 among a 
high-risk group 
of 154,425 
individuals 
India ܥெൌ ܥௌ ? ? ?ǡ ? ? ?כ ݌݋݌ெವ 
ܦெൌ ܦௌ ? ? ?ǡ ? ? ?כ ݌݋݌ெವ 
Wilford et al. 
(2012) 
Total cost for 
2,780 patients 
2007 US$ DALYs averted 
among 2,780 
patients 
Malawi ܥெൌ ܥௌȀ ?ǡ ? ? ?כ ݌݋݌ெವ ܦெൌ ܦௌȀ ?ǡ ? ? ?כ ݌݋݌ெವ 
 
A3.4.3 Numbers of cases (or patients) and realistic coverage levels 
Data on costs and DALYs averted by intervention enables the comparison of different interventions 
by cost-effectiveness.  In order to determine the net benefit associated with each intervention, data 
on the size of the population that would benefit is also required.  This data was obtained from CHAI 
from their 2014 costing.  For each intervention the target population (e.g. pregnant women, women 
in need of PMTCT, etc.) in need is given for each of 192 interventions.  CHAI also provided estimates 
of realistically attainable coverage levels obtained from a bottleneck analysis as part of their 2014 
costing. 
 
A3.4.4 Per case (or patient) costs 
Although per patient costs could be obtained from the papers, as shown in Table A7, the costs 
provided by the papers may not reflect the cost of providing the intervention in Malawi.  In addition, 
costs are often given as discounted lifetime costs.  Malawi specific drug and supply costs for each 
intervention from the 2014 costing mid-term review were made available by Palladium and CHAI, 
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and these more accurately reflect the costs associated with each intervention for the purposes of 
deciding the budget.  As such, the latter were used in estimating the scale of the package.   
 
Using one source of cost data for ICER and net benefit calculations and another to determine the 
scale of the package can be cause for confusion.  As an example the issue noted in Footnote 18 in 
Section 3 is presented here.  If the costs used in ICER and net benefit calculations are the same as 
those used in calculating the cost of the package, forcing an intervention into the optimal package 
which is not already included on the basis of cost-effectiveness will necessarily reduce the total  
DALYs averted by the package.  However, if separate costs are used (i.e. costs from a study are used 
to calculate ICERs and net benefit while Malawi specific annual costs are used to determine the cost 
of the package), the following scenario becomes possible: if the intervention that is being forced in 
has a lower per patient cost in Malawi than what was reported in the paper, and if it forces out 
interventions that have a higher per patient cost in Malawi than what was reported in the paper, this 
trade may actually increase aggregate DALYs averted.   
 
In the report, disinvestment decisions are made on the basis of cost-effectiveness as calculated by 
using the cost data from the original source paper to determine an ICER.  The least cost-effective 
interventions based on ICERs are removed until the package is within budget (where budget is based 
on the Malawi costs).  This is reasonable as it is the lifetime costs and effects of different 
interventions that determine their relative cost-effectiveness, but it is the annual cost of provision 
ƚŚĂƚŵĂƚƚĞƌƐĨŽƌĞĂĐŚǇĞĂƌ ?ƐďƵĚŐĞƚ ? 
 
Ideally, Malawi-specific fully loaded, lifetime costs associated with delivering each intervention 
would be used in the calculation of ICERs.  Obtaining this data is something to aspire for in future 
work.  In the absence of reliable data on this, cost data from the region as presented in the original 
studies is a good second best option. 
 
A3.5 Summary of data collected and future use by Ministry of Health and partners 
The draft EHP presented in this report represents only a first take on the use of potentially available 
data.  Ministry of Health and development partners must now take responsibility for updating, 
improving and ensuring appropriate use of the framework on an ongoing basis. 
 
The interventions that have been included in the living data library were limited to those included in 
the 2014 EHP OneHealth Tool costing exercise conducted by CHAI.  The rationale for this was that it 
ensured the availability of necessary data on number of cases (or patients), realistic coverage levels 
and per case (or patient) costs leaving only estimates of cost-effectiveness to be added, which could 
be obtained externally.  In addition, this covered all interventions contained within Ministry of 
Health disease programme strategic plans.  The OneHealth costing exercise included 167 
interventions.  From among these there were Malawi cost data for 133 (80%), coverage data for 143 
(93%), and case or patient numbers for 143 (86%).  This resulted in 117 interventions for which cost, 
coverage and case or patient numbers were available.  ICERs were obtained for 67 (57%) of these 
117 interventions.  As cost-effectiveness data was not found for all of these interventions, and the 
plans do not represent an exhaustive list of all interventions that could be considered for 
implementation in Malawi, the data included so far in the library is, therefore, only a first take on 
the available literature and the search for additional data sources for a wider range of interventions 
must continue. 
 
Moreover, the intervention lists and data sources used are time limited.  They will have to be 
updated as new interventions become available, clinical and other evidence evolves, and prices 
change.  National disease programme guidelines are intermittently revised as international 
recommendations change (e.g. World Health Organization clinical guidelines) and new evidence 
becomes available, and the funding environment and healthcare delivery will evolve through the 
lifetime of the Health Sector Strategic Plan.  The Ministry of Health and partners will, therefore, need 
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to establish suitable processes for continually seeking the best evidence reflects the situation in 
Malawi to populate and update the library to support resource allocation decisions. 
 
In the longer term, it should be hoped more evidence is generated within Malawi rather than having 
to rely on secondary sources drawn from healthcare systems that may differ in important ways for 
Malawi.  As such the EHP framework can help to prioritise where new information in Malawi would 
be most valuable. 
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